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ABSTRACT 
 
Mitoxantrone (MTX) is a chemotherapeutic agent that emerged as an alternative to 
anthracycline therapy. However, the use of MTX is also related to late cardiotoxicity 
whose mechanisms remain largely unknown. Thus, the present thesis aims to highlight 
the underlying mechanisms involved in the MTX-induced cardiotoxicity, namely the effects 
related to mitochondria and metabolism, using in vivo and in vitro models. The in vitro 
models employed in the present work were hepatic S9 fractions and mitochondria, both 
isolated from Wistar male adult rats and H9c2 culture cells. The Wistar rat was the in vivo 
model used. 
MTX (concentrations from 10nM to 100µM) elicited a time- and concentration-
dependent cytotoxicity in H2c9 cells. Two therapeutic concentrations (100nM and 1µM) 
and three time-points were selected (24, 48, and 96h) for further studies. Both MTX 
concentrations caused a significant increase in caspase-3 activity at 24h. Significant 
decreases were observed in the total and reduced glutathione levels only in MTX 100nM 
at 96h, however neither alterations in oxidized glutathione, nor increases in 
malondialdehyde levels were observed in any time or concentrations tested. On the other 
hand, changes in the intracellular ATP levels, mitochondrial membrane potential, and 
intracellular calcium levels were observed in both concentrations and all time-points 
tested. Noteworthy, for the first time, decreased levels of ATP-synthase expression and 
activity and increases in the reactive species generation were observed at 96h in both 
MTX working concentrations. However, neither the radical scavenger N-acetylcysteine nor 
the mitochondrial function enhancer L-carnitine prevented MTX cytotoxicity.  
As evidenced by the in vitro study in H9c2, MTX causes cytotoxicity in therapeutic 
concentrations, then, the following approaches aimed to disclosure the principal 
mechanisms of MTX-induced toxicity, mainly focusing on MTX metabolism and MTX-
induced mitochondrionopathy. The metabolic studies started with the use of hepatic S9 
fractions isolated from rats incubated for 4h with MTX (100µM), whose products were 
analyzed through liquid chromatography coupled with mass spectrometry. After a 4h 
incubation, the MTX content was 35% lower and five metabolites were identified: an 
acetoxy ester derivative never described before, two glutathione conjugates, the MTX 
monocarboxylic acid derivative, and the MTX naphtoquinoxaline. Noteworthy, the 
presence of MTX and of the naphtoquinoxaline metabolite was also evidenced in vivo in 
liver and heart after 7.5mg/kg MTX-administration in rats. Then, the potential cytotoxic 
effects of MTX and MTX plus metabolites were evaluated in the H9c2 cells after 24h 
incubation with MTX alone and MTX after S9 metabolization. The cytotoxicity caused by 
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MTX plus metabolites was higher than that observed in the H9c2 cells incubated with non-
metabolized MTX group. Moreover, the co-incubation of MTX with CYP450 and CYP2E1 
inhibitors partially prevented the cytotoxicity observed in the MTX groups incubated with 
H9c2 cells, highlighting that the metabolism of MTX is relevant for its undesirable effects. 
However, increases in caspase-3 activity caused by MTX incubation were not prevented 
by co-incubation with CYP450 or CYP2E1 inhibitors in this cell model. 
To evaluate the cardiac mitochondrial toxicity of MTX, male Wistar rats were treated 
with three cycles of 2.5mg/kg MTX at day 0, 10, and 20. One treated group was 
euthanized on day 22 (MTX22) to evaluate early MTX cardiac toxic effects while the other 
was euthanized on day 48 (MTX48), to allow the evaluation of MTX late effects. MTX 
treatment caused a reduction in relative body weight gain in both treated groups with no 
significant changes in water and food intake. Increased cardiac relative mass was 
observed in MTX22 group and microscopic changes suggestive of dilated cardiomyopathy 
were evident in both treated groups. Considering mitochondrial effects, it was shown, for 
the first time that MTX induced an increase in the activity of both complex IV and complex 
V in MTX22 group, while the decrease in the complex V activity was accompanied by the 
reduction of ATP content in the MTX48 rats. Despite the MTX-induced cardiotoxicity 
evidenced in our study, we also observed hematotoxicity and direct hepatotoxicity upon 
this MTX administration regimen. 
In summary, this thesis highlights the relevance of CYP450- and CYP2E1-mediated 
metabolism to the MTX-induced cytotoxicity. Moreover, it was shown that energetic crisis 
observed after MTX incubation/administration acts as a possible key factor in the cell 
injury. MTX presents the potential to cause mitochondrionopathy as demonstrated both by 
in vivo and in vitro approaches.  
 
Keywords: Mitoxantrone. Metabolism. Cardiotoxicity. Mitochondrionopathy. 
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RESUMO 
 
A mitoxantrona (MTX) é um agente antineoplásico que foi sintetizado com o intuito 
de ser uma alternativa à terapia com antraciclinas. Contudo, o uso clínico da MTX 
também tem sido associado ao desenvolvimento de cardiotoxicidade tardia, a exemplo do 
que é observado na terapia com antraciclinas. Os mecanismos envolvidos na 
cardiotoxicidade descrita não foram ainda devidamente elucidados. Assim, os estudos 
desenvolvidos no âmbito desta tese tiveram como objetivo esclarecer os principais 
mecanismos associados à cardiotoxicidade induzida pela MTX, nomeadamente no que 
diz respeito à influência do seu metabolismo e os efeitos adversos cardíacos ao nível 
mitocondrial, recorrendo a modelos in vivo e in vitro. Os modelos in vitro utilizados nestes 
trabalhos foram as frações S9 hepáticas e mitocôndrias, ambas isoladas de ratos Wistar 
adultos e a linha celular imortalizada H9c2. O rato Wistar foi o modelo in vivo utilizado.  
As células H9c2 foram incubadas com diferentes concentrações de MTX (10nM a 
100µM) por 24, 48, 72, ou 96h, observando-se uma citotoxicidade dependente da 
concentração e do tempo de incubação. Selecionou-se para os estudos subsequentes 
duas concentrações de MTX consideradas clinicamente relevantes (100nM e 1µM) e três 
tempos de incubação (24, 48, e 96h). Ambas as concentrações de MTX causaram 
aumentos significativos na atividade da caspase-3 após 24h de incubação. Após 96h, 
observou-se ainda uma redução significativa nos níveis intracelulares de glutationa total e 
reduzida, mas apenas com a concentração de 100nM de MTX. Contudo, não foram 
observadas alterações nos níveis de glutationa oxidada ou nos níveis de malondialdeído 
em nenhuma concentração e tempo de incubação testados. Por outro lado, observou-se 
alterações nos níveis intracelulares de ATP, assim como o aumento do potencial de 
membrana mitocondrial e dos níveis intracelulares de cálcio em todos os tempos 
avaliados. Observou-se, ainda, pela primeira vez, que a MTX nas concentrações 
selecionadas e após 96h de incubação, originou uma diminuição da expressão e da 
atividade da ATP sintetase, acompanhada pelo aumento na formação de espécies 
reativas. Contudo, nem a co-incubação com N-acetilcisteína (um captador de espécies 
reativas) ou com a L-carnitina (um potenciador da função mitocondrial) preveniu a 
citotoxicidade induzida pela MTX nestas células. 
Os estudos metabólicos foram realizados incubando MTX (100µM) com frações S9 
isoladas de fígado de ratos Wistar adultos. Ao fim de 4h de incubação, os produtos do 
metabolismo da MTX foram extraídos e analisados utilizando cromatografia em fase 
líquida acoplada com detetor de massa. Após 4h de incubação com as frações S9 
hepáticas, o conteúdo de MTX foi 35% inferior à quantidade inicialmente adicionada ao 
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sistema. Além disso, cinco metabolitos foram identificados: um acetoxi éster nunca antes 
descrito, dois conjugados com glutationa, um derivado do ácido monocarboxílico e o 
derivado naftoquinoxalínico da MTX. De realçar que a presença da MTX e do seu 
derivado naftoquinoxalínico também foi detetada in vivo nos fígados e corações de ratos 
tratados com 7.5mg/kg de MTX. De seguida, os efeitos citotóxicos da MTX sem qualquer 
metabolismo e da MTX após biotransformação obtida através destas incubações foram 
avaliados através da incubação por 24h com as células H9c2. A citotoxicidade causada 
pela MTX em presença de seus metabolitos foi significativamente maior que a observada 
nas células incubadas apenas com MTX. A co-incubação de MTX com os inibidores do 
metabolismo mediado pela CYP450 e CYP2E1 preveniu parcialmente a citotoxicidade, 
provando que o metabolismo da MTX é relevante para os seus efeitos tóxicos. Contudo, 
o aumento na atividade da caspase-3 observada após 24h de incubação com a MTX 
(100nM e 1µM) não foi prevenido pela co-incubação com os inibidores da CYP450 ou 
CYP2E1. 
Para avaliar a toxicidade cardíaca mitocondrial in vivo exercida pela MTX, 
utilizamos como modelo animal ratos machos Wistar tratados com três ciclos de MTX 
(2.5mg/kg) nos dias 0, 10 e 20. Um dos grupos tratados com MTX foi eutanasiado no dia 
22 (MTX22) para avaliar os efeitos cardiotóxicos da MTX logo após o seu último ciclo. O 
outro grupo foi eutanasiado no dia 48 (MTX48) a fim de avaliar os efeitos cardiotóxicos 
tardios causados pelo fármaco. O tratamento com MTX causou uma redução no aumento 
de massa corporal relativa nos dois grupos que receberam MTX, alteração que não foi 
acompanhada por mudanças nos consumos de água e ração. Observou-se, também, um 
aumento na massa relativa dos corações no grupo MTX48 e alterações microscópicas 
compatíveis com cardiomiopatia dilatada nos dois grupos. A administração de MTX 
causou um aumento na atividade dos complexos IV e V mitocondriais no grupo MTX22 e 
uma diminuição na atividade do complexo V mitocondrial, acompanhada pela redução 
nos níveis cardíacos de ATP no grupo MTX48. Foi ainda possível observar efeitos tóxicos 
hematológicos e uma possível hepatotoxicidade direta causada pela administração de 
MTX neste modelo animal e condições experimentais.  
Em conclusão, este estudo contribuiu para demonstrar a relevância do metabolismo 
mediado pela CYP450 e CYP2E1 para os efeitos cardiotóxicos relacionados com a MTX. 
Além disso, observou-se que um dos principais mecanismos de cardiotoxicidade da MTX 
envolve o estabelecimento de uma falha energética, conforme demonstrado através dos 
efeitos tóxicos mitocondriais observados nos modelos in vivo e in vitro utilizados. 
 
Palavras-chave: Mitoxantrona. Metabolismo. Cardiotoxicidade. Toxicidade 
mitocondrial. 
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I.1. Historic context 
Mitoxantrone (MTX) is a chemotherapeutic agent that belongs to the 
anthracenedione chemical group (Figure 1). This chemical group comprises naturally 
occurring quinones present in plants or animals that due to their intense color were used 
as dyes since ancient times (1). Despite the lack of antitumor activity of many naturally 
occurring quinones, the anthracycline antibiotics doxorubicin and daunorubicin, which 
contain the anthracenedione ring framework in their tetracyclic chromophore part are 
ranked as one of the most effective anti-cancer drugs ever developed (1–4). However, 
due to the serious toxicity presented and difficulties experienced in the synthesis of 
anthracycline, molecules with only the anthracenedione group seemed to be a good 
alternative to be explored as anticancer drugs (1). In fact, structural variations conducted 
in the laboratory resulted in active bis-substituted aminoanthracenedione derivatives with 
significant antitumor activity such as ametantrone (1,5). Trying to increase the antitumor 
activity of these compounds, structural variations resulted in the MTX molecule in 1979 
(1,6–8). 
 
Figure 1: Chemical structure of MTX. The chromophore ring is highlighted in red. 
 
The chemical synthesis of MTX involves the reaction of leuco-1,4,5,8-tetra-
hydroxyanthraquinone with 2-[(2-aminoethyl)amino]ethanol. The product of this reaction is 
further aromatized with chloranil (9). Nowadays, MTX is a medicine supplied as a dark-
blue solution in vials, containing 2mg/ml (Novantrone® or mitoxantrone dihydrochloride). 
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I.2. MTX chemical aspects 
MTX is a crystalline, hygroscopic blue powder with melting point of 160-162ºC or 
203-205ºC (for the dihydrochloride form) (9). It is sparingly soluble (from 30 to 100 parts of 
solvent for one part of solute) in water, slightly soluble (from 100 to 1,000 parts of solvent 
for one part of solute) in methanol, and practically insoluble (more than 10,000 parts of 
solvent for one part of solute) in organic solvents such as acetone, acetonitrile, and 
chloroform (9,10).  
In aqueous solution, MTX presents a relevant adsorption to materials such as glass 
and filters (1). Moreover, MTX reacts with sodium metabisulfite and EDTA (10). Solutions 
containing MTX are stabilized by the addition of 0.5% ascorbic acid (10). Additionally, 
MTX is stable in spiked whole blood for 3-6 hours (h) if samples are kept on ice and in 
plasma samples for at least 24h (10,11). After reconstitution with 0.9% sodium chloride or 
5% dextrose, MTX is stable for at least 48h (1). 
I.3. Therapeutic uses 
MTX is a Food and Drug Administration (FDA) approved chemotherapeutic agent in 
the treatment of malignances such as myelogenous acute leukemia and prostate cancer 
and in the treatment of multiple sclerosis (secondary progressive, progressive relapsing, 
or worsening relapsing-remitting) to reduce neurologic disability and/or frequency of 
clinical relapses (2,12,13). Furthermore, MTX is also used in the treatment of acute 
lymphoid leukemia and as an initial approach in adults for the treatment of acute non-
lymphocytic leukemia (which can include myelogenous, promyelocytic, monocytic and 
erythroid acute leukemia), bone marrow transplant, breast cancer, head and neck cancer, 
liver carcinoma, malignant lymphoma, non-Hodgkin’s lymphoma, ovarian cancer, and 
solid tumors (12).  
In general, MTX chemotherapy protocol in humans consists on the administration of 
MTX for 30 minutes (min) via continuous infusion (1,9). The usual doses and dosing 
regimen for MTX indications are summarized on Table 1. It is important to note that the 
chemotherapy schedule might be individually adjusted taking into account the disease 
progression and the clinical condition of the patient, especially when the optimal dose and 
timing is not defined, as it occurs in the non-FDA labeled indications (12). In these 
situations, many intravenous (i.v.) administration regimens and intervals are described in 
the literature, namely a single dose every 28 days, 24h infusion, continuous infusion over 
five or 21 days, three times a day, five times a day, weekly and even high dose regimen 
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for refractory lymphoma employing 90mg/m2 MTX were already described (1,14). 
Moreover, the safety and effectiveness parameters of most MTX uses in pediatric patients 
are not well established, but in such patients presenting solid tumor configuration, the 
recommended dose is 5 to 8mg/m2/week i.v. or an alternative dosing regimen of 18 to 
20mg/m2 i.v. every three to four weeks (12). 
 
Table 1: MTX usual adult dose regimen protocols. 
Disease Dose regimen protocol References 
Acute myeloid leukemia 
 
Induction phase: 12mg/m2/day i.v. on days one to 
three in combination with cytarabine 
(100mg/m2/day) as continuous i.v. 24h infusion on 
days one to seven; if leukemia persists, a second 
induction course of 12mg/m2/day i.v. for two days 
in combination with cytarabine (100mg/m2) daily as 
continuous i.v. 24h infusion on days one to five 
may be given; 12mg/m2/day i.v. over 30min on 
days one, three, and five with cytarabine 
(25mg/m2) once as an i.v. bolus followed by 
100mg/m2/day as a continuous i.v. infusion for 10 
days and etoposide (100mg/m2) i.v. over 1h on 
days one to five  
Consolidation phase: 12mg/m2/day i.v. on days 
one and two in combination with cytarabine (100 
mg/m2/day) as continuous 24h i.v. infusion on days 
one to five; 12mg/m2/day i.v. over 30min for three 
days (on days four to six) with cytarabine 
(500mg/m2) i.v. over 2h every 12h on days one to 
six  
 
(12) 
Multiple sclerosis 
 
Prostate cancer 
 
12mg/m2 i.v. every three months 
 
12 to 14mg/m2 i.v. every 21 days 
 
(12,15) 
 
(2,12) 
Metastatic breast cancer and 
non-Hodgking’s lymphoma, 
hepatoma 
Monotherapy: First dose of 14mg/m2 i.v. This 
administration might be repeated after 21 days if 
blood counts return to normal/acceptable values. 
Patients presenting myelosupression at the 
beginning of treatment may receive a lower dose 
of 2mg/m2.  
Combined therapy: 10 to 12mg/m2 as the initial 
dose.  
(16) 
 
In acute myeloid leukemia, the induction phase is the first course of treatment and it 
aims to induce total remission, which is characterized by the absence of blasts in the 
peripheral blood and the presence of ≤ 5% blasts in bone marrow smears (17). After 
reaching this stage, the consolidation phase aims to maintain the total remission. Thus, in 
the referred acute myeloid leukemia treatment, the antimetabolic agent cytarabine is 
commonly associated to MTX, as described in the Table 1. Another drug associated to 
MTX to deal with cancer relapse or refractory to conventional primary chemotherapy is 
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etoposide (16). Recently, a prospective multicenter phase two trial assessed a novel 
regimen protocol for T-cell prolymphocytic leukemia based on induction by fludarabine 
(25mg/m2/day, i.v., on days one through three), MTX (8mg/m2/day, i.v., on day one), and 
cyclophosphamide (200mg/m2/day on days one and three, repeated on day 28), up to four 
cycles, followed by alemtuzumab in the consolidation phase (30mg i.v. three times weekly 
for a maximum of 12 weeks) (18). 
It is also important to point that, due to the toxicity profile of MTX, its dose regimen is 
limited to the maximum cumulative dose of 140mg/m2 (2). Due to the apparent increased 
susceptibility of multiple sclerosis patients to cardiotoxicity, some authors state that 
maximum cumulative dosage in multiple sclerosis patients might be defined as 100mg/m2 
(19,20). Furthermore, MTX administration is not recommended in patients with a baseline 
neutrophil count of less than 1500 cells/mm3 (unless the patient is receiving MTX for the 
treatment of acute nonlymphocytic leukemia) (12). Moreover, in patients with hepatic 
impairment, the dosage adjustment is necessary and in patients with multiple sclerosis 
presenting this condition, MTX use is not indicated (12). All these aspects are discussed 
in more detail in the next sections. 
I.4. Pharmacological action mechanisms 
MTX is a deoxyribonucleic acid (DNA) intercalating agent that causes single and 
double breaks in the DNA by the stabilization of a complex formed between DNA and 
topoisomerase II (1,2,21). The planar electron-rich chromophore group of MTX (Figure 1) 
is essential for its ability to intercalate in the DNA strains (21). This interaction is 
completed by electrostatic interactions of MTX side chains with the anionic exterior of the 
DNA (1,21). As a consequence, MTX inhibits the DNA replication, the ribonucleic acid 
(RNA) transcription, and also promotes the cell cycle arrest (1,22). Moreover, epigenetic 
effects of MTX were evidenced using purified isolated histones. The incubation with MTX 
(0.1-100µM) demonstrated the high affinity of MTX to histone H1 and core histone 
proteins, suggesting an additional target of this drug (23). 
Due to its immunosuppressive capacity, MTX is also employed to suppress active 
inflammation preventing myelin and axonal damage observed in multiple sclerosis (15). 
MTX induces short- and long-term immunosuppressive effects leading to the induction of 
apoptosis in antigen-presenting cells and the induction of cell lysis, which results in 
reduced levels of blood leukocytes and inhibition of the proliferation of all types of immune 
cells (15,24). MTX inhibits lymphocytes (T cells and B cells) activity and suppresses the 
expression of pro-inflammatory molecules such as prostaglandin, C-reactive protein, 
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cytokines (TNF-α, IL-1β, IL-6, IL-12, and IL-23), and lipopolysaccharide induction of nitric 
oxide production by astrocyte (1,15,25). The clinical effects of MTX in multiple sclerosis 
are suggested to last up to one year after the end of treatment (15,24). As a 
consequence, a reduction in the neurological disability and/or the frequency of clinical 
relapses is expected (2). 
I.5. Pharmacokinetics 
I.5.1. Absorption and distribution 
The i.v. route is the preferential via of MTX administration (1,26). Intravenously 
administered MTX rapidly disappears from plasma due to the distribution to highly 
perfused organs in humans and laboratory animals (1,26). The MTX distribution half-life is 
about 15min (1,26) and studies are consistent to report very high volumes of distribution 
associated to MTX therapy (1,2,14,26). Thus, in humans, the best fit for the plasma-
concentration curve is reached in a 3-compartment model (1). In patients with refractory 
lymphoma, after 30min i.v. infusion (15mg/m2 or 90mg/m2), the mean maximum MTX 
plasma concentrations were about 1.5 and 12µM, respectively. The volume of distribution 
at steady state (486 ± 254L/m2) was shown to be independent of the dose (14). Firstly, the 
concentration in peripheral cells is higher than plasmatic levels (1,14). In cancer patients, 
35 days after a single i.v. dose of 12mg/m2 C14-labeled MTX, the wide distribution volume 
of MTX was corroborated (26). The tissues that present higher MTX content were the liver 
(1140ng/g wet tissue), soon followed by pancreas (1040ng/g wet tissue), thyroid (958ng/g 
wet tissue), spleen (733ng/g wet tissue), heart (716ng/g wet tissue), stomach (555ng/g 
wet tissue), lymph node (432ng/g wet tissue), kidney (312ng/g wet tissue), lung (276ng/g 
wet tissue), small intestine (173ng/g wet tissue), and bone marrow (78ng/g wet tissue) 
(26). From the best of our knowledge, there are no data regarding pharmacokinetic 
parameters of MTX orally administered in humans because it is not intended for use as an 
oral medication (26).  
In animal models, when administered intramuscularly, significant amounts of MTX 
remain at the muscular tissue used in the administration. For example, in dogs, 16.2% of 
the intramuscular administrated MTX dose (0.37mg/kg) persisted at the injection site for 
ten days (26). In mice, the single intramuscular administration of MTX at doses 0.3mg/kg 
and 3mg/kg resulted in the intramuscular retention of 17.6% and 8.9% of MTX, 
respectively, for at least 24h (26). Besides being an erratic pathway for MTX 
administration, the intramuscular via should be avoided because there is increased risk of 
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extravasation with consequent tissue necrosis when MTX is injected into a muscle, 
subcutaneously, or into spinal cord (2,15). Thus, in humans, this via is irrelevant. 
I.5.2. Metabolism 
MTX metabolism has been evaluated through in vivo and in vitro studies. It was 
already described in human, pig, and rat (27). Regarding in vitro protocols, studies using 
exogenously added isolated enzymes, such as NADPH cytochrome P450 reductase 
(28,29), peroxidase enzyme systems (27,30), primary cultures of hepatocytes isolated 
from rats, rabbits, and humans (31), microsomes, and cytosol fractions isolated from rat 
liver (32) were performed. 
The metabolism of MTX involves phase I, phase II, and phase III reactions. MTX 
main metabolic products are the naphtoquinoxaline metabolite (Figure 2) and its 
respective oxidation products, MTX mono- and dicarboxilic derivatives, and MTX 
conjugated with reduced glutathione (GSH) and glucuronic acid. Regarding the 
interspecies variability, mono- and dicarboxylic acid derivatives of MTX are major products 
of human and rabbit hepatic metabolism, while in rats they are residual (27,31). 
Concerning phase I reactions, the oxidoreductive metabolism of MTX is mediated by 
the microsomal system and/or peroxidase enzymes such as human neutrophil 
myeloperoxidase (33,34). Chemically, the position of the hydroxyethylamino group on the 
chromophore ring produces steric hindrance, impairing the one-electron reductase-
mediated metabolism of MTX (35). Thus, MTX possess a lower one-electron reduction 
potential compared to others analogues (35). Hence, since the one-electron reduction of 
MTX is not facilitated, the preferential pathway of MTX metabolism is the two-electron 
reduction (33,36,37), which generates more stable products when compared to the semi-
quinone radicals produced by one-electron reduction (33). 
As already mentioned, oxidative metabolism of MTX is of great interest since its 
byproducts seem to be involved in the MTX cytotoxic action (33,36,37). This hypothesis is 
supported by the observation that MTX has particular effectiveness in tumors with high 
contents of peroxidases and that the cellular sensitivity to MTX damage is proportional to 
cell metabolic skills (27,30,37). Additionally, the inhibitory effect of MTX (5µM) on cell 
growth in hepatoma cells (HepG2) was prevented after the blockage of cytochrome P450 
metabolism by the co-incubation with metyrapone (MTP) (0.5mM) (33). In another study, 
the inhibition of cytochrome P450 metabolism with the same inhibitor (MTP 1mM) in the 
same cell line (HepG2) and in rat isolated hepatocytes resulted in the total loss of MTX-
induced cytotoxicity, even with high doses of MTX (200 to 400µM incubated for 4 and 9h), 
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leading the authors to assume that, without suffering metabolism, MTX has a negligible 
toxic effect in those models (37). Accordingly, in a human breast cancer cell model, the 
co-incubation of MTP (0.5mM) also prevented the cytotoxicity observed with MTX (5 to 
200µM) (36).  
Still regarding oxidative metabolism of MTX, it was suggested that epoxide 
hydrolase might contribute to MTX detoxification since its inhibition leads to increased 
MTX cytotoxicity. Thus, it suggests that at least one toxic relevant metabolite of MTX is an 
epoxide (33). 
The main studies aiming to elucidate the chemical structures of MTX metabolites 
are summarized on Table 2. Until now, the most pharmacological relevant MTX oxidation 
product is the naphtoquinoxaline metabolite (Figure 2), which presents cytotoxic features 
(37,38).This metabolite was already identified in human, rat, and pig after MTX 
administration (27). 
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Phase II metabolism enzymes are protagonists in the MTX detoxification process, 
namely the conjugation with GSH and glucuronic acid (1,27,32,37).  
 
 
 
 
Figure 2: Chemical structure of 8,11-dihydroxy-4-(2-hydroxyethyl)-6-[[2-[(2-
hydroxyethyl)amino]ethyl]amino]-1,2,3,4,7,12-hexahydronaphto-[2-3]-quinoxaline-7-12-
dione or naphtoquinoxaline, the main bioactive metabolite of MTX. 
 
Efflux transporters are often recognized as phase III metabolism (39,40). MTX is 
substrate of the adenosine 5′-triphosphate (ATP)-binding cassette G2 (ABCG2) 
transporter or breast cancer resistance protein (BCRP), which works as a multidrug 
resistance pump (41). Furthermore, a study using a BCRP and P-glycoprotein inhibitor 
(GF-120918 10mg/kg, administered via jugular vein cannula) co-administered to rats 
receiving MTX (2mg/kg, administered via jugular vein cannula) demonstrates that BCRP 
or P-glycoprotein, or both, elicit an important role in the MTX biliary excretion (42). In fact, 
MTX is described as a substrate of BCRP, although, its transport via P-glycoprotein 
occurs in a minor extent (42). It is an important observation as in cancer treatment, the 
drug extrusion is associated to the resistance to MTX therapy, thus, currently several 
studies are focused on the development of new formulations/vehicles or functionalized 
nanoparticles to overcome drug resistance (43). 
I.5.3. Elimination 
The redistribution of the MTX sequestered in the tissues back to the plasma and its 
elimination from the body is a slow process (26). Indeed, the long-term pharmacological 
and even toxicological effects attributed to MTX might be related to its long cellular 
residence time and its strong affinity for cellular macromolecules and membranes (35,44). 
The majority of excretion studies are designed measuring the radioactivity in the urine and 
feces after MTX labeled administration instead of identifying the metabolites chemical 
structures (1). In humans and laboratory animals, biliary excretion is the main elimination 
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route of unchanged MTX and its conjugated metabolites, although, less amounts can be 
found in urine (1,26,37,42,45). 
I.6. Adverse effects 
As an aggressive chemotherapy drug, MTX treatment has been associated to 
several undesirable effects, such as myelosupression, nausea, vomiting, diarrhea, 
mucositis, and hepatotoxicity (1,9,12,46). Myelosupression manifests as severe 
neutropenia, and sometimes the administration of colony stimulating factors such as 
filgrastim or sargramostim is recommended. Blood transfusion may be needed in patients 
presenting severe thrombocytopenia, anemia, or hemorrhage (12). MTX is classified as a 
drug with low emetic risk (47). However, the management of MTX-induced nausea and 
vomiting is done with dexamethasone and metoclopramide (47). MTX has a high 
extravasation risk, being a vesicant agent (2). If extravasation occurs, the infusion must be 
discontinued and the affected area should be elevated (12).  
The most concerning MTX adverse effect is the late cardiotoxicity due to its life-
threatening risk (2,13), followed by the hematotoxicity and hepatotoxicity, due to their high 
frequency (2,9,12). Due to their relevance, since they can limit the therapy, these MTX-
related toxicities will be addressed separately in independent sub-sections.  
The mean lethal dose (LD50) of MTX in experimental animals was set at 5mg/kg in 
rats, 10mg/kg in mice, and 10mg/m2 in beagle dogs (9,48). As already stated, besides the 
symptoms commonly related to chemotherapy, namely nausea, fatigue, diarrhea, 
alopecia, anorexia, and mucositis, the toxic effects associated with MTX treatment include 
hematotoxicity (2,9), significant hepatotoxicity (9,49), and serious and (sometimes 
irreversible) cardiotoxicity (2,9,20,46). 
I.6.1. MTX-induced cardiotoxicity 
MTX was produced with the goal to overcome the cardiotoxicity observed with 
anthracyclines such as doxorubicin, the prototype of the group. However, MTX has been 
also reported as cardiotoxic in humans, affecting up to 18% of treated patients 
(2,13,50,51). 
The majority of MTX-induced cardiotoxicity manifests as congestive cardiac failure 
characterized by the reduction left ventricular ejection fraction (LVEF) (13). Other cardiac 
disturbances such as tachycardia, dysrhythmias, and chest pain were also reported as 
MTX cardiac side effects (12). In cancer treatment, risk factors for the development of 
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MTX-related cardiotoxicity include previous treatment with anthracyclines, mediastinal 
radiotherapy, pre-existing cardiovascular disease, and cumulative doses superior to 
140mg/m2 (2,13). Additionally, patients presenting LVEF < 50% cannot receive MTX 
(13,52). Thus, monitoring the cardiac function is recommended after a cumulative dose of 
80mg/m2 (2). A reduction of about 10% in the LVEF baseline associated with an absolute 
LVEF value less than 50% should be viewed with concern and cessation of MTX therapy 
is recommended (13,52,53). The main limitation of this approach is its low sensitivity to 
detect cardiotoxicity at early stage. Monitoring based only in the LVEF values do not allow 
preventive strategies since it detects myocardial damage only when a functional 
impairment has already occurred (53). Hence, measurement of cardiac troponin has 
proven to help the early identification of patients susceptible to develop myocardial 
dysfunction and cardiac events (53). 
Despite the most common manifestation of MTX-induced cardiotoxicity is decrease 
in LVEF, less frequent symptoms are disturbances of heart rhythm (12,54). The 2h 
incubation of isolated guinea pig ventricular myocytes with MTX (30µM) induced a time-
dependent prolongation of action potential duration occasionally accompanied by early 
after depolarization (55), which can contribute to the proarrhythmic effect attributed to 
MTX. Additionally, in the same study, it was demonstrated that the same MTX working 
concentration (30µM) caused the depression of both inward rectifier potassium current 
and delayed rectifier potassium current (which can induce torsades de pointes), the 
blockage of 93% the muscarinic-gated receptor potassium current evoked by 1µM 
carbamylcholine incubation, while it did not affect the L-type calcium channels (55).  
Regarding human reports, a female patient, 55 years old, presenting a relapse of 
acute myelogenous leukemia was admitted to reinduction therapy with MTX (10mg/m2, 
i.v.) and etoposide (100mg/m2, i.v.), daily, for five doses. About 22min after her fifth dose, 
the patient presented chest tightness and bradycardia, which was reverted with the 
discontinuation of the drug. She was rechallenged twice in a monitored setting and the 
symptoms recurred (54). It is important to point out that this patient was subjected to a 
previous regimen of chemotherapy months before, namely an induction chemotherapy 
(cytarabine, etoposide, and idarubicin in a cumulative dose of 36mg/m2) followed by the 
consolidation phase with high dose of cytarabine. Furthermore, other medications that the 
patient received in that moment included acyclovir, ciprofloxacin, allopurinol, granisetron, 
potassium chloride, magnesium sulfate, and lorazepam. Thus, possibly, the previous 
anthracycline therapy contributed to the cardiotoxic reaction observed in this patient (54).  
Patients with multiple sclerosis seem more susceptible to cardiac adverse effects 
due to the higher frequency of low baseline LVEF observed in untreated patients 
compared to individuals without multiple sclerosis (13,46). In these patients, the 
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cardiotoxicity occurs at a median of 7.2 cycles of MTX (12mg/m2, every three months, 
cumulative dose of 86.4mg/m2) (19), but it can occur before. In a prospective study, 28 
multiple sclerosis patients treated with MTX were subjected to a LVEF evaluation before 
receiving the fourth cycle of MTX. The results revealed that, at that moment, five patients 
(17.8%) already underwent a significant decline in their baseline LVEF (13). It suggests 
that MTX-cardiotoxicity could be evident at lower doses and earlier in multiple sclerosis 
patients (46) and thus, such patients treated with MTX should be followed warily. The 
monitoring of cardiac function includes a baseline echocardiogram followed by 
echocardiograms at one and two years and even every cycle of MTX (19). Conservative 
authors claim that the maximum cumulative dosage in such patients might be defined as 
100mg/m2 (19,20). Therefore, in multiple sclerosis, the use of MTX is recommended only 
in cases of very aggressive multiple sclerosis, presenting increased disability, frequent 
and severe relapses, and many active inflammatory lesions (20).  
In multiple sclerosis, MTX treatment frequently induces clinical asymptomatic 
reduction of baseline LVEF, which is counteracted, returning to normal values, after MTX 
end of therapy (19,20,56,57). In a review of clinical data from 18 multiple sclerosis 
patients who received MTX dosage (12 patients received 12mg/m2; two patients received 
10mg/m2, two patients started with 15mg/m2 and were kept with cycles of 8mg/m2, two 
patients started with 15mg/m2 and were gradually lowered to 12 and 8mg/m2) and interval 
cycles (12 patients followed the conventional three months interval, two patients 
alternated three and two months courses, one patient performed three cycles with three 
months interval, three cycles of four months and the last three cycles of two months 
intervals, and the last three patients followed a one month interval course) depending on 
the clinical response and side-effects. Cardiac LVEF decrease was observed in all MTX 
treated patients, but only two cases presented severe LVEF decrease (LVEF<55%, 
considered below the normal values). These patients received only two drug infusions and 
were advised to discontinue the therapy although they were clinically asymptomatic. 
Following this procedure their LVEF returned to normal values (56).  
In a retrospective review of 128 patients with multiple sclerosis treated with MTX 
standard protocol (using as top limit the cumulative dose of 120mg/m2), it was observed 
that until the end of the study (median follow-up duration of 14 months), 18 (14%) patients 
developed de novo cardiotoxicity evidenced by decreased LVEF (46). Of these patients, 
only three (17%) recovered to normal in the next assessment, six had no further follow-up, 
and two remained altered until the end of the study (46).  
In a single center, open-label, non-randomized study, 42 secondary progressive 
multiple sclerosis patients were divided in two groups: control (n=11, receiving no 
treatment) and MTX (n=31, receiving 12mg/m2 infusion every three months up to a 
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maximum cumulative dose of 120mg/m2) (20). Ten patients from the MTX group 
prematurely finished the study due to cardiac complications (heart palpitations, pulmonary 
edema, and tachycardia). These cardiac complications were classified as severe 
(decrease of 10% or more from the LVEF baseline) in six patients. However, the post-trial 
cardiac surveillance, which continued for up two years, revealed that 48% of the total MTX 
patients presented decreases in the LVEF, that followed by a post-treatment recovered to 
normal cardiac function (20). 
In another open-label study with 23 multiple sclerosis patients receiving 12mg/m2 at 
three month intervals (up to a maximum cumulative dose of 140mg/m2) only one patient, 
representing 4.3% of the studied population, presented asymptomatic left ventricular 
hypokinesia and reduced LVEF, which was also reverted after the end of therapy (57). 
This lower cardiotoxicity incidence might be related to the reduced number of patients.  
A retrospective study reviewing 41 multiple sclerosis patients who received MTX 
previously (12mg/m2 at three month intervals), evidenced that 9% presented decline 
greater than 20% from baseline LVEF and 7% patients had decline greater than 10% from 
baseline LVEF (19). Of patients re-evaluated off-study, all presented improvements in 
LVEF, also demonstrating that, although the MTX-induced cardiotoxicity is a concern, it 
may be not permanent if the therapy is conducted with regularly monitoring and 
interruption is in place adequately (19). 
There are few studies trying to elucidate the mechanisms involved in the MTX-
induced cardiotoxicity. Frequently, regarding that the clinical manifestations of MTX-
cardiotoxicity are similar to those observed to doxorubicin, it was believed that both 
compounds shared the mechanisms involved in their cardiotoxicity (29,58). However, 
other studies suggest that the mechanisms are dissimilar (50,59). Considering that the 
purpose of the present thesis is to contribute to the elucidation of the mechanisms related 
to MTX-cardiotoxicity, mechanistic studies will be discussed in more details in the 
Discussion section. 
I.6.2. MTX-induced hepatotoxicity 
The occurrence of abnormalities in the liver function during the treatment of complex 
diseases such as cancer and multiple sclerosis can be catastrophic. In fact, it may 
compromise treatment and even, as a consequence of impaired metabolism, contribute to 
MTX toxicity (60). In humans, the MTX-induced hepatotoxicity manifests as transient 
increases in the serum bilirubin concentration and in the activity of hepatic enzymes, 
occurring in about 15% of treated patients (12mg/m2) (9,15). 
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There are few studies focusing on the hepatotoxicity of MTX and it is still unclear 
whether the hepatic disturbances elicited by MTX are due to a direct hepatotoxic effect or 
are a consequence of cardiac failure. The hepatotoxicity was observed in mice treated 
with a single dose of MTX (15mg/kg), which hepatic injury was considered more intense 
compared to the hepatic lesion promoted by doxorubicin in the same dose and model 
(49). Existing data demonstrate that oxidative stress is involved in the hepatic injury 
caused by MTX (33,37,49). A study with HepG2 cell line and rat hepatocytes suggested 
that the cytotoxic effect of MTX depends on prior oxidation mediated by CYP450 (37). The 
incubation of MTX (100µM) with HepG2 cells for 6h promoted a slight decrease in the 
GSH levels (33) that is in accordance with what was found in mice, where decreases in 
the hepatic antioxidant defenses after MTX treatment were also observed (49). In fact, 
four days after the intraperitoneal (i.p.) injection of a single dose of MTX (15mg/kg), 
intense signals of hepatic lipid peroxidation, diminished activity of hepatic superoxide 
dismutase, catalase, and glutathione peroxidase, and depletion of the hepatic retinol and 
GSH contents were observed (49). In the same study, hepatic histopathologic results 
showed intense hydropic vacuolization of the cytoplasm, necrotic areas, picnosis, and 
nuclear lysis (49). 
As mentioned above, in vitro studies suggest that the oxidative biotransformation 
influences MTX toxicity (33,36,37). Hence, the liver is the main destiny of MTX 
accumulation in humans (26) and, as already described, is also in charge of the MTX 
detoxifying process through phase II metabolism (1). Thus, it is not surprising that patients 
presenting hepatic disturbances are prescribed with lower dose of MTX (15). 
I.6.3. MTX-induced hematotoxicity 
As already addressed, after administration MTX is rapidly attracted to blood cells, 
causing immediately its hematological effects (1). In fact, concerns were raised since the 
observation that, 1h after MTX infusion, its concentration in leukemic cells is ten times 
higher than in plasma and 350 times higher after 2-5h (9). On the other hand, MTX 
depressor effects among blood cells, namely macrophage, T and B cells proliferation 
justify its use in the treatment of multiple sclerosis (51). 
MTX presents a potential hematotoxicity which can limit and even cause the 
cessation of therapy (9,61). Firstly, the administration of MTX only can be supported after 
hematological screening: patients with baseline neutrophil counts ≤ 1,500 cells/mm3 
should not receive MTX (51). The hematotoxicity of MTX involves myelosuppression that 
manifests mostly as leukopenia, thus being its main dose-limiting effect (9,61). Low 
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hemoglobin (Hb) levels were observed in 21 of 139 (15%) multiple sclerosis patients 
treated with MTX (12mg/m2, i.v., monthly for three months until reaching the cumulative 
dose of 120mg/m2) (46). The same study observed that anemia was associated with 
increasing dose and that only women manifested this condition (46). In a study employing 
high dose regimens (40 to 80mg/m2) by i.v. 15min administration, the myelosuppression 
was universal (62), which is in agreement with the high frequency associated with MTX 
treatment (2,9,24). In a phase II clinical trial, 93% advanced breast cancer patients who 
received MTX (starting dose of 10mg/m2) associated with paclitaxel (175mg/m2) 
presented leukopenia, which was considered severe in 67% of the patients (63). The 
administration of MTX (38mg/m2), via i.p., demonstrated that the observed leukopenia is 
transient since white blood cell (WBC) counting returned to normal values within 7 days 
(61). Curiously, patients treated with higher dose regimens tend to present a faster blood 
count recovery (2). Nonetheless, WBC should be carefully monitored since in severe 
cases of leukopenia, complications such as sepsis and other infections can occur (64). 
During MTX pharmacological use, thrombocytopenia also occurs, but in a lesser 
extent than neutropenia (9). In most cases, neutropenia and thrombocytopenia are mild 
(2). Monitoring hematological parameters during MTX-therapy is recommended and drug 
discontinuation or dose reduction may be warranted with neutrophil counts ≤ 1,000 
cells/mm3 or other signals of strong myelosuppresion (51). However, in spite of the 
relevance of MTX-induced myelotoxicity, patients treated with MTX require fewer median 
platelet (PLT) transfusions and are treated with fewer median days of i.v. antibiotics 
compared to those that received other chemotherapy drugs such as daunorubicin (2). 
In MTX-treated patients undergoing autologous bone marrow transplantation, the 
time of transplant has to be carefully assessed depending on the dose and individual 
pharmacological profile. It is an important observation since MTX treatment increases the 
risk of delayed hematopoetic function recovery (14). 
Consistent with the long accumulation and sustained efficacy of MTX, the 
hematotoxicity of MTX also can emerge after the end of treatment (15). In fact, the most 
serious hematologic manifestation is the development of MTX-associated leukemia, which 
is also related with other topoisomerase II inhibitors (2). The mechanism involved in the 
secondary leukemia is still being debated. One hypothesis is that the chromosomal breaks 
related to perturbations in the topoisomerase II cleavage-religation equilibrium post 
topoisomerase II inhibition can lead to DNA recombination and the resulting translocations 
are responsible for the leukemogenesis (65). The most common chromosomal 
translocations related to the topoisomerase II inhibitors-induced leukemia involve 
rearrangements in the gene mll, chromosome 11q23 (2,17,65). 
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The occurrence of secondary leukemia is related to familiar history of neoplasia, the 
concomitant use of other anti-cancer drugs, chemotherapy doses and regimen, and 
individual immunological condition (17). In most cases, patients develop secondary acute 
myelogenic leukemia, however, some patients develop acute lymphoblastic leukemia (2). 
The pattern of acute myelogenic leukemia related to topoisomerase II inhibitors treatment 
is characterized by a short latent period (usually one year) and it is not associated with a 
myelodysplastic phase prior to its manifestation (2,17). Trying to avoid the associated 
leukemia in multiple sclerosis patients, MTX administration is not recommended in 
patients with previous history of leukemia (15). However, the use of MTX in the treatment 
of multiple sclerosis has been accompanied by reports of leukemia associated to MTX 
therapy in patients without previous diagnosis of hematological disorders (2,51). Thus, 
considering the long-term hematological disturbances, blood cell counts should be 
continued even after the cessation of MTX therapy (15). 
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II. General objective 
In the Introduction section, the therapeutic actions of MTX (as an antineoplastic 
agent and in the treatment of multiple sclerosis) and the limitations related to its adverse 
effects and toxicity (cardiotoxicity, hepatotoxicity, and hematotoxicity) were focused in 
detail. Noteworthy, several case reports were presented evidencing the potential MTX-
induced cardiotoxicity (20,46,52,54). However, the mechanisms underlying this toxicity are 
still not fully elucidated, as will be described in more detail in the Discussion section. 
The general objective of the present thesis was to contribute to the clarification of 
the mechanisms involved in the MTX-induced cardiotoxicity. Additionally, in this work, it 
was intended to highlight the relevance of MTX metabolic pathways and the mitochondrial 
role in that process. Finally, it was intended to correlate the effects and mechanisms 
studied in in vitro systems (cellular fractions, organelles, and cell line cultures) to those 
observed in in vivo model (adult male Wistar rats). 
II.1. Specific objectives: 
 Evaluation of MTX mechanisms of cytotoxicity, through the assessment of viability, 
oxidative stress, energetic, and mitochondrial parameters after MTX incubation in a 
cardiomyoblast model (H9c2 cells). 
 Evaluation of the in vitro mitochondrial toxicity through the assessment of 
mitochondrial membrane potential, ATP synthase expression and activity after MTX 
incubation with H9c2 cells.  
 Evaluation of the direct mitochondrial toxic effect through the assessment of 
mitochondrial membrane potential after MTX incubation with cardiac mitochondria isolated 
from male Wistar rats. 
 Evaluation of the in vivo cardiotoxicity through the assessment of cardiac optic and 
transmission electron microscopy, cardiac protein, glutathione, and ATP levels after the 
administration of three cycles of MTX to male Wistar rats. 
 Ex vivo evaluation of mitochondrial toxicity through the measurement of 
mitochondrial membrane potential and complex IV and V activities of the respiratory chain 
of cardiac mitochondria isolated from male Wistar rats treated with three cycles of MTX. 
 Evaluation of the metabolic profile of MTX through the identification of the 
metabolites generated after the incubation of MTX with hepatic S9 fractions isolated from 
rats. 
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 Evaluation of the contribution of MTX metabolism to its cardiotoxicity using 
in vitro promoted metabolism coupled to cytotoxic assays in H9c2 cell line. 
 Evaluation of the in vivo MTX cumulative sub-chronic toxicity through the 
assessment of biochemical parameters evaluating cardiac, hepatic, and renal 
function, hematological parameters, and hepatic measurements (microscopy, 
hepatic glutathione and ATP levels) after the administration of three cycles of MTX 
to male Wistar rats. 
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In the present section, all experimental models and protocols employed in this thesis 
will be addressed. 
III.1. Brief considerations on the experimental models and 
concentrations used in the studies 
III.1.1. In vitro models 
In the present thesis, three in vitro models were used, namely hepatic S9 fractions, 
the H9c2 cell line, and isolated mitochondria from heart of adult rat. In general, the in vitro 
models have some advantages when mechanistic studies are being performed (66). It is 
well known that the detection of cardiovascular injury at the cellular level can be 
complicated by interactions between adjacent cells of different types, metabolism of the 
toxic agent under investigation, and by alterations in the concentration of the xenobiotic at 
the cell-body fluid interface (67). Thus, an important advantage of in vitro models is to 
allow a better control of the surrounding environment (66), which is imperative in the 
assessment of cardiotoxicity since humoral, neuronal, and endocrine influences are 
commonly considered confounding factors in the evaluation of cardiotoxicity in vivo (68). 
Another feature is the fact that in vitro studies involve the sacrifice of fewer animals 
compared to in vivo approaches, evidencing an ethical advantage (66). 
III.1.1.1. Hepatic S9 fractions isolated from adult male Wistar rat 
The hepatic S9 fraction is the supernatant obtained after liver homogenization and 
centrifugation at 9,000g for 20min in a suitable medium (100mM phosphate buffer, pH 
7.4). The greatest advantage of this model is the fact that it contains the cytosol (with 
most of the enzymes responsible for the phase II metabolism, such as glutathione-S-
transferases and some enzymes responsible for phase I metabolism, as cytosolic epoxide 
hydrolase) and microsomes (containing enzymes of phase I metabolism such as CYP450 
isoforms and UDP-glucuronosyl transferases responsible for phase II metabolism) (69–
71). Hence, liver S9 fractions are reported as the most representative sub-cellular in vitro 
system to study metabolism because it allows the study of the main biotransformation 
phases at the same time (71), being much more illustrative of a real situation than studies 
using isolated enzymes or microsomes (69,71). Indeed, S9 fractions can be considered a 
classic model since it is commonly used in the pharmaceutical industry coupled to Ames 
test in order to evaluate the possible mutagenic effect after bioactivation of pre-genotoxic 
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compounds (72–74). Moreover, procedures involved in liver S9 fractions isolation and 
incubation steps are rapid, do not require sophisticated equipment, are easy to perform in 
laboratory settings, and allow the study of several conditions with a single animal. 
In the study using hepatic S9 fractions isolated from male Wistar rats presented in 
this thesis (Manuscript I), the animals used received phenobarbital 0.2% in drinking water 
for one week prior to the excision of the livers. This approach aims to induce enzymes 
involved in the MTX metabolism (32,75) and was adopted due to the difficulties to 
simulate in vitro MTX oxidoreductive metabolism, being commonly used by other authors 
(28,31–33). In fact, phenobarbital induces CYP450-induced metabolism as well as other 
enzymatic systems present in the S9 fractions, namely epoxide hydrolase, UDP-
glucuronyl transferases, and glutathione-S-transferases (76).  
III.1.1.2. H9c2 cell line 
Permanent cell lines are frequently used as a model for many cell types (77). 
However, immortal cardiac cell lines have been difficult to establish because of the 
heterogeneity of cells present in heart tissue, the inability of isolated cardiomyocytes to 
multiply in culture, and the low frequency of cardiac tumors necessary to create cell lines 
(77,78). The studies presented in the Manuscripts I and II on the next section were 
conducted in the H9c2 cellular model. This clonal muscle cell line derived from embryonic 
rat heart tissue was established in 1976 by Kimes and Brandt. It was obtained through 
selective serial passage from BDIX rat cardioblasts (79). 
Morphologically, H9c2 cells are spindle-shaped cells. The dividing myoblasts are 
large, flat, and their nuclei contain from two to four spherical or lobed nucleoli (78,79). The 
structures and organelles that can be observed in the H9c2 cells are: microtubules 
(sometimes arranged as a dense network), vacuoles, lysosomes, pinocytotic vesicles, 
basement membrane, ribosomes, cell surface enlarged by microvilli, and a rich content of 
mitochondria and rough endoplasmic reticulum (78,79). Golgi cisternae are found near the 
cell nucleus and caveolae are absent (78). At low densities, H9c2 cells organize 
themselves avoiding close contact (Figure 3 A). On the other hand, when they reach 
confluence, they arranged themselves in linear parallel arrays, maintaining these 
characteristics at continual passages (Figure 3 B) (79). 
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Figure 3: Phase contrast micrographs of H9c2 cells. A) at low densities; B) at confluence 
(79). 
 
Binding studies for 1,4-dihydropyridine demonstrated H9c2 heart-specific features 
(78). Additionally, after reaching confluence, H9c2 cells express an L-type calcium current 
characterized by a slow time course of inactivation, unitary conductance properties, and 
sensitivity to organic calcium channel blockers, typical characteristics of cardiac cells 
(78,80). Moreover, at least 2 distinct potassium channels and a nonspecific cation channel 
were described (80). Densely culture conditions seems to optimize calcium channel 
expression, since when cells are in the proliferative phase, these channels are sparse 
(80). However, if H9c2 cells are allowed to reach confluence, the myoblastic population 
becomes depleted faster (81). In order to prevent this inconvenient, cell cultures used in 
this thesis were kept at 70-80% confluence. The H9c2 cells also have features of skeletal 
muscle, namely the tendency of myoblasts to form myotubes, the synthesis of muscle-
specific creatine phosphokinase isoenzyme when the mononucleated myoblasts fuse, and 
the expression of nicotinic receptors (79).  
The pattern of membranous signal-transducing G-proteins found in the H9c2 cells 
shows all characteristics of striated muscle cells (78). They contain two forms of the Gs α-
subunit, two forms of the Giα-subunit, and, as adult rat cardiomyocytes, they lack G0 
subunit (78). H9c2 cells also contain β1 and β2 adrenoreceptors and respond to 
acetylcholine stimulation (81,82). Regarding caveolin, a major structural protein of 
caveolae involved in the AMPc signaling, it was demonstrated that caveolin-1 mRNA 
expression is similar in H9c2 cells and in canine hearts (83). However, the mRNA of 
muscle-specific subtype caveolin-3 is abundantly expressed in cardiac tissues while 
poorly in the H9c2 cells (83). Decreased levels of caveolin-3 expression were associated 
with the development of cardiac hypertrophy since caveolin-3 regulates the inhibition of 
cell growth and proliferation in the heart (84). Recently, a study comparing the response 
patterns after hypertrophic stimulation in primary cardiomyocytes from neonatal rat heart 
and in the H9c2 cell line demonstrated that both models showed almost identical 
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hypertrophic responses (85). Hence, it was concluded that H9c2 cells are a reliable model 
for the study of drug-induced hypertrophy with the ethical advantage of being an animal-
free protocol, in opposition to neonatal cardiomyocytes (85). 
In the present study, we used the H9c2 cells in the undifferentiated state. In this 
condition, the embryonic-derived H9c2 cells are more reliant on glycolysis accordingly 
with the fetal phenotype (86). This cellular model expresses thyreoglobulin at the mRNA 
and protein level. That is an important regulator of cardiac function and cardiovascular 
hemodynamics (87).  
Significant levels of peptidylglycine α-amidating monooxygenase, which catalyzes 
the formation of bioactive α-amidated peptides from glycine precursors, are found in the 
H9c2 myoblasts. This observation suggests the ability of H9c2 to make bioactive α-
amidated hormones and neuropeptides, however, the activity of this enzyme is lower than 
in atrium tissues (88). Although the role of peptidylglycine α-amidating monooxygenase in 
the heart tissue is not fully elucidated, it seems that amidated peptides have a crucial role 
in the early stages of cardiac development (88). 
Furthermore, these myoblasts express multiple CYPs at comparable levels to those 
expressed in the rat heart. CYP1A1 and CYP1B1 are constitutively expressed in both 
H9c2 cell line and rat heart, CYP2B1, CYP2B2, CYP2E1, CYP2J3 are expressed in the 
H9c2 cells at different degrees but in comparable levels to rat heart, and CYP2A1, 
CYP3A1, CYP3A2 are not expressed either in H9c2 cells or in the rat heart (89). Hence, 
regarding their metabolic competence, H9c2 cells have been considered a valuable in 
vitro model to study cardiac drug metabolization and the metabolic capacity of the heart 
(89). 
In conclusion, in spite of the H9c2 cellular model characteristics of muscle cells, it 
preserves several elements of cardiac cells, namely the electrical and hormonal signal 
pathways (78,79). Thus, this in vitro model has been widely accepted as a feasible model 
to study cardiotoxicity (90–93). 
III.1.1.3. Cardiac mitochondria isolated from male Wistar rat 
Mitochondria are responsible for supplying between 80-90% of total ATP produced 
in the cell (94). Due to the high energetic demand in the cardiac muscle, mitochondria 
occupy 20-30% of cell volume, being the highest distribution of these organelles found in 
the cardiomyocytes, showing mitochondria relevance for the cardiac performance (94–
96). Thus, given their importance, one of the main objectives of this thesis was to 
investigate mitochondria as a target for the MTX-induced cardiotoxicity. For this purpose, 
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cardiac mitochondria isolated from male Wistar rats were used. Similarly, this model was 
already employed in the evaluation of the doxorubicin-induced mitochondrionopathy (97–
99). 
III.1.2. In vivo model 
For the in vivo studies, the laboratory animal model used was Rattus novergicus. 
This animal species is recognized as the most widely in vivo model used in medical 
research and, in toxicology, the rodent species of choice (100,101). The advantages of 
working with rats comprises the easier monitoring of their physiology, and, in many cases, 
the physiology is resembled to human conditions (100). Additionally, other advantages 
include metabolic similarities to humans, their relatively docile nature, short life span, short 
gestation period, and the large database of rat nutrition, diseases, and general biology 
(101). Regarding cardiovascular system, the rat is considered an excellent model, 
especially for stroke and hypertension (100). This animal model has been widely used in 
the assessment of chemotherapy-induced cardiotoxicity (102,103). Another advantage is 
that the size of the rat enables both the easy manipulation of the animal in laboratory 
conditions and serial blood draws (100).  
Adult male Wistar rats (Charles River Laboratories, Barcelona, Spain) were housed 
in cages, with a temperature- and humidity- controlled environment. Food and water were 
provided ad libitum and animals were subjected to a 12h light-dark cycle. Animal 
experiments were approved by the Ethics Committee of the Faculty of Pharmacy, Porto 
University, Portugal (protocol number 9/04/2013). Housing and experimental treatment of 
the animals were in accordance with the Guide for the Care and Use of Laboratory 
Animals from the Institute for Laboratory Research.  
In the experiments presented in the Manuscripts III and IV, one week prior the 
experiment, animals were acclimatized in the cages and then were distributed into three 
groups (five animals per group): control, MTX22, and MTX48. Animals were treated by i.p. 
via with three cycles, (5ml/kg), of saline solution (0.9% NaCl) (control) or MTX 2.5mg/kg 
(MTX22 and MTX48) on day 0, 10, and 20. The MTX treated groups reached a total 
cumulative dose of 7.5mg/kg on day 20, as represented in Figure 4. The regimen of 
administration (one cycle every ten days) was performed aiming to simulate the 
chemotherapeutic cycles that comprise several administrations. The interval of ten days 
was defined taking into account the life cycle of the rat and the clinical conditions 
observed in pilot studies. The MTX22 group suffered euthanasia on day 22, in order to 
assess the MTX-induced cumulative damage 48h after the last cycle of treatment. MTX48 
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group suffered euthanasia on day 48, 28 days after the last cycle of treatment, with the 
objective to evaluate late cumulative responses. 
 
Figure 4: Graphic representation of the in vivo experiment design performed in 
Manuscript III and IV. 
 
During the experiment, daily clinical evaluations of all animals were performed by 
the veterinary doctor of the team. The parameters evaluated were piloerection, 
dehydration, hemorrhage and diarrhea, motor function (tone and movement coordination), 
breathing (rate and depth, gasping), mucosal color (pale, cyanotic), and clinical signals of 
abdominal pain. The individual weight and consumption of food and water were also 
recorded every day until the day 30. On the day of euthanasia, animals were anesthetized 
with xylasine/ketamine (10mg/kg/100mg/kg) and blood was collected through cardiac 
puncture. 
The in vivo metabolic study presented in the Manuscript I was also performed 
aiming to verify the presence of MTX metabolites in liver and heart after MTX i.p. 
administration to male Wistar rats. Three animals received a single dose of 7.5mg/kg of 
MTX i.p., and were euthanized 24h after treatment under anesthesia with 
xylasine/ketamine (10mg/kg/100mg/kg). The livers and hearts were excised and MTX and 
its metabolites were extracted as described in the Manuscript I to the LC-diode array 
(DAD)/electrospray ionization interface (ESI)-MS analysis. 
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III.1.3. MTX concentrations and doses 
The human conventional doses of MTX are summarized in the Table 3. The mean 
maximum plasma concentrations in humans after a 15mg/m2 or a 90mg/m2 30min infusion 
of MTX are about 1.5 and 12µM, respectively (14). Considering tissue levels, it is well 
known that MTX is extensively distributed and largely accumulates in heart tissue (104). In 
humans, MTX is detected in the organism for a long period, reaching the amount of 
716ng/g wet weight in the heart even 35 days after a single dose (12mg/m2) (26), 
evidencing the cardiac accumulation of MTX. 
Considering MTX plasma and tissue concentration levels, the MTX working 
concentrations were selected in order resemble therapeutically relevant concentrations. 
Thus, for the in vitro evaluation of the cytotoxic effects upon H9c2 cells, time and 
concentration response curves were performed using the low MTX concentrations of 
10nM, 100nM, 1µM, 5µM, 10µM, 50µM, and 100µM. Afterward, given the cytotoxic profile 
in this model, experiments were performed using the MTX selected concentrations of 
100nM and 1µM.  
 
Table 3: MTX conventional dose for FDA approved therapeutic indications in humans. 
Therapeutic indication MTX dose Maximum cumulative dose References
Acute myeloid leukemia   12mg/m2/Day 140mg/m2 (2,12) 
Prostate cancer 12mg/m2 i.v. every three months 140mg/m2 (2,12) 
Multiple sclerosis 12 to 14mg/m2 i.v. every 21 days 100mg/m2 (12,19,20)
 
Regarding the in vivo experiment, the dose was also calculated considering 
previously pilot studies employing three cycles of 2.5mg/kg, 5mg/kg, and 10mg/kg. The 
body surface area of the rats was also considered in order to correlate the dose in this 
species with the human top limit of MTX doses. Thus, the majority of experiments were 
performed using three cycles of MTX 2.5mg/kg (7.5mg/kg as cumulative dose), which 
corresponds to 16mg/m2 of a rat weighing 240g, by allometric relationship. The metabolic 
in vivo study was conducted using the single dose of 7.5mg/kg, administered via i.p., in 
order to correlate with the total cumulative dose used in the in vivo study of the MTX-
induced cardiotoxicity and to reach the limit of detection of the analytical method used. 
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III.2. Methods 
III.2.2. Evaluation of the metabolic profile of MTX using hepatic S9 
fractions by LC-DAD/ESI-MS 
The metabolic profile of MTX was evaluated using hepatic S9 fractions isolated from 
male Wistar rats (32). Three tubes were incubated and further analyzed in order to assess 
MTX metabolism: 
 Blank tube: control supplemented S9 fractions (without MTX), in order to 
evaluate possible matrix interferences; 
 Control tube: 100µM MTX + 1mM NADPH + 4mM GSH (without the S9 
fractions), in order to rule out the possibility of artifact formation; 
 Sample: supplemented S9 fractions + 100µM MTX, in order to assess the MTX 
metabolism at times 0 and 4h. 
At 0 and 4h, after samples collection, methanol was added (ratio of 1:4 methanol) in 
order to precipitate the proteins and to extract MTX and the metabolites. Methanol was 
evaporated under nitrogen flow and the residue was re-suspended in 200µl phosphate 
buffer saline (for cytotoxicity evaluation) or in 200µl methanol (for LC-DAD/ESI-MS 
analysis). The experimental protocol of S9 fractions isolation, protein quantification, 
incubation conditions, and LC-DAD/ESI-MS analysis are described in details in 
Manuscript I. 
III.2.3. Cytotoxicity assays 
The cytotoxicity assays employed to evaluate the toxic effects of MTX in the H9c2 
cells were the lactate dehydrogenase release (LDH) assay (which correlates with the loss 
of cell membrane integrity) and the reduction of the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (which can be used as a mitochondrial viability 
index since it measures mostly the action of mitochondrial dehydrogenases). 
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III.2.3.1. LDH leakage Assay 
At the end of incubation period (24, 48, 72, and 96h), cellular damage was 
quantitatively assessed by the evaluation of cell membrane integrity through the 
measurement of LDH release by means of a kinetic photometric assay. The % of viability 
was evaluated considering the % of LDH released over the total LDH from the complete 
lysis of the cells (artificially promoted by the addition of triton X-100). The absorbance was 
measured at 340 nm in a multi-well plate reader (BioTech Instruments, Vermont, US). 
III.2.3.2. MTT reduction assay 
The cytotoxic effects of MTX after the incubation period (24, 48, 72, and 96h) were 
assessed also through the reduction of MTT assay as previously described (105).The 
reduction of the MTT assay can be used as a mitochondrial viability index since it 
measures mostly the action of mitochondrial dehydrogenases (106). 
Trying to prevent or counteract the observed cytotoxicity of MTX, potential protective 
studies were performed by co-incubating the agents with MTX (100nM and 1μM) at 37 ºC 
for 96h. The protective agents employed were: a) the reactive species scavenger and 
GSH precursor N-acetylcysteine (NAC) (1mM), b) the energetic function enhancer L-
carnitine (1mM), c) the CYP450 inhibitor MTP (0.5mM), and the CYP2E1 inhibitor diallyl 
sulfide (DAS) (150µM) (105). 
III.2.4. Caspase-3 activity assay 
Caspase-3 is a cysteine protease involved in apoptosis, being activated by both 
intrinsic and extrinsic pathways (107). Caspase-3 activity was assessed after 24h 
incubation with MTX (100nM and 1µM) in H9c2 cells through the method previously 
described (108). The CYP450 inhibitor MTP (0.5mM) and the CYP2E1 inhibitor DAS 
(150µM) were used to possible counteract the activation of caspase-3 caused by MTX 
(105) (Manuscript II).  
 
 
 
 
Experimental Section _____________________________________________________________ 
36 
III.2.5. Evaluation of oxidative stress 
III.2.5.1. Evaluation of reactive species generation 
Early and late generation of reactive species was evaluated in the H9c2 cells after 
incubation with MTX (100nM and 1µM) using two different probes, dihydrorhodamine 
(DHR) (100µM) (108) or dichlorodihydrofluorescein diacetate (DCFH-DA) (10µM) 
(109,110). Both are non-fluorescent probes that undergo intracellular oxidation to their 
respective fluorescent products in the presence of reactive species such as peroxynitrite, 
and hydroxyl radical (108,111,112). The experimental protocol is described in detail in the 
Manuscript II. 
III.2.5.2. Measurement of intracellular total glutathione (GSHt), GSH, 
and oxidized glutathione (GSSG) levels 
The glutathione status was evaluated after incubation with MTX (100nM and 1µM) in 
the H9c2 cells. It was also evaluated in liver and heart of male Wistar rats after the 
administration of MTX (3 cycles of 2.5mg/kg). The glutathione status was assessed by the 
5,5-dithio-bis(2-nitrobenzoic) acid (DTNB)-GSSG reductase recycling assay, as previously 
described (113,114), and the experimental protocols are described in Manuscript II, III, 
and IV. 
III.2.5.3. Evaluation of lipid peroxidation 
Malondialdehyde is the most used marker of lipid peroxidation (115). The main 
method employed to the malondialdehyde quantification is the thiobarbituric acid (TBA) 
reactive substances (TBARS) assay (116,117). However, this methodology is not specific 
since TBA also reacts with a variety of compounds such as sugars, aminoacids, 
aldehydes, and bilirubin, generating colorimetric interferences (116). Thus, trying to 
counteract this problem, we employed a previously validated HPLC/UV method, with 
minor adaptations, which presents an extraction step employing butanol that reduces the 
interferences, being more reliable (116). The protocol is described in the Manuscript II. 
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III.2.6. Evaluation of the energetic function 
III.2.6.1. Measurement of ATP levels 
ATP determinations were performed after incubation with MTX (100nM and 1µM) in 
the H9c2 cells and in vivo (liver and heart), after the administration of MTX (three cycles of 
2.5mg/kg) to male Wistar rats. The ATP levels were measured through the 
bioluminescence test (118), as described in Manuscript II, III, and IV. 
III.2.6.2. Evaluation of the ATP synthase expression 
ATP synthase expression was evaluated in the H9c2 cells after incubation with MTX 
through western immunoblot (119). The experimental conditions are described in details in 
the Manuscript II.  
III.2.6.3. Evaluation of the ATP synthase activity 
The activity of ATP synthase in the H9c2 cells was indirectly determined by analysis 
of the inorganic phosphate (Pi) released from ATP hydrolysis (119) (experimental protocol 
described in the Manuscript II). 
III.2.6.4. Blue native polyacrylamide gel electrophoresis (BN-PAGE) 
separation of cardiac mitochondria membrane complexes of MTX-treated rats 
The respiratory chain complexes from cardiac mitochondria of MTX treated rats 
(three cycles of 2.5mg/kg) were evaluated. Mitochondrial isolation and BN-Page 
separation of the respiratory chain complexes are described in the Manuscript III. 
III.2.6.5. In-gel activity of mitochondrial complexes IV and V after 
MTX treatment 
The in-gel activity of cardiac mitochondrial complexes IV and V of control or MTX 
treated rats (three cycles of 2.5mg/kg) were evaluated. The in-gel activity of complexes IV 
and V were determined using the methods previously described (95) (Manuscript III). 
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III.2.6.6. Cardiac mitochondrial DNA quantitation in MTX treated rats 
Cardiac mitochondrial DNA of control or MTX treated rats (three cycles of 2.5mg/kg) 
were quantified using the Qubit® dsDNA BR assay kit. Samples were read in a Qubit® 2.0 
Fluoremeter and results are expressed as the ratio between the mitochondrial DNA 
concentration and heart mass. 
III.2.7. Evaluation of the mitochondrial membrane potential after in 
vivo and in vitro treatment with MTX 
Cardiac mitochondria from control and MTX48 rats were isolated for the assessment 
of the late and cumulative effects induced by MTX towards the mitochondrial membrane 
potential. Moreover, an in vitro study with mitochondria isolated from control rat heart (not 
treated with MTX) was also performed in order to assess the direct MTX-induced effects 
in the mitochondrial function after incubation with MTX (10nM, 100nM, and 1µM).   
The evaluation of the mitochondrial function was performed through the 
measurement of the mitochondrial membrane potential and it was assessed using an ion-
selective electrode to measure the distribution of the tetraphenylphosphonium (TPP+), as 
described before (120) (Manuscript III).  
III.2.8. Flow cytometry analysis 
Intracellular calcium measurements and the evaluation of the mitochondrial 
membrane potential in the H9c2 cells were determined through flow cytometry using the 
Fluo-3 AM (10µM) and TMRM (20nM) fluorescent probes, respectively, following the 
experimental protocols described in the Manuscript II. 
III.2.9. Heart and liver preparation for light and transmission electron 
microscopy 
Heart and liver of MTX treated rats were microscopically evaluated through light and 
transmission electron histology (121). Samples were processed as described in detail in 
the Manuscript III and IV.  
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III.2.10. Plasma biochemical analysis 
Plasma parameters of control and both MTX treated rats (three cycles of 2.5mg/kg) 
were evaluated. On the day of euthanasia, blood was collected into heparinized tubes. 
Plasma levels of albumin, total proteins, IgG, IgM, IgE, C3 and C4 complement, total and 
conjugated bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), alkaline 
phosphatase, transferrin, ferritin, iron, cholesterol, triglycerides, glucose, amylase, 
creatinine, urea, uric acid, potassium, sodium, calcium, C-reactive protein, α1 – antitrypsin, 
δ-glutamyltranspeptidase (GGT), and LDH, creatine kinase (CK), CK-MB, and lactate 
were evaluated in duplicate on an AutoAnalyzer (PRESTIGE® 24i, PZ Cormay S.A.) using 
the respective kits and following the manufacturer instructions. 
III.2.11. Hematological analysis 
Hematologic parameters of control or MTX treated rats (three cycles of 2.5mg/kg) 
were evaluated. On the day of euthanasia, blood samples (using EDTA as anticoagulant) 
were collected and processed in order to obtain whole blood. We evaluated the 
erythrocyte count, Hb concentration, hematocrit (HCT), hematimetric indexes – mean cell 
volume (MCV), mean cell hemoglobin (MCH), mean cell hemoglobin concentration 
(MCHC), red cell distribution width (RDW), PLT, plateletcrit (PCT), platelet distribution 
width (PDW), mean platelet volume (MPV), and WBC count, by using an automated blood 
cell counter (Sysmex K1000, Hamburg, Germany). Differential leukocyte count was 
performed on blood smears stained according to Wright (122). Reticulocyte count was 
performed by microscopic counting on blood smears after vital staining with new 
methylene blue (Reticulocyte stain, Sigma-Aldrich, St Louis, MO, USA). 
III.2.12. Total protein quantification 
Except when otherwise specified, the protein levels were determined by Lowry 
method (123). Samples were suspended in NaOH 0.3M and protein content were 
evaluated spectrophotometrically using a microplate reader (750nm) (114). 
III.2.13. Statistical analysis 
Results are presented as means ± standard deviation. The evaluations of the rat 
relative body weight gain and the consumptions of food and water were followed daily. 
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Thus, the statistical analysis was performed using repeated measures ANOVA followed 
by the Student Newman Keuls post hoc test. In the other experiments, statistical 
comparisons between groups were performed with One-Way ANOVA (in case of normal 
distribution) or Kruskal-Wallis test (one-way ANOVA on ranks – in case distribution is not 
normal). Significance was accepted at p values <0.05.  
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The major findings of this thesis were the elucidation of the mechanisms involved in 
the MTX-induced cardiotoxicity, mainly regarding its metabolism and energetic status 
changes. The metabolic profile of MTX after incubation with rat hepatic S9 fractions was 
described and MTX and the MTX-naphtoquinoxaline metabolite were found in extracts of 
heart and liver of male Wistar rats previously injected (24h before, i.p.) with MTX. The 
presence of MTX metabolites increased the MTX cytotoxicity in a cardiomyoblast in vitro 
model (H9c2) and, in the same model, the cell damage was partially prevented by the 
inhibition of the CYP450 metabolism and specifically of the CYP2E1 isoenzyme 
metabolism, highlighting the relevance of MTX metabolism to its cardiotoxicity. Our results 
also suggest an important mitochondrial toxicity evidenced both in vitro and in vivo, which 
is characterized by an energetic gap observed by decreases in the ATP levels and 
disturbances in the mitochondrial complexes. Noteworthy, at the late time point (96h) the 
onset of an oxidative stress phenomenon at the in vitro model was observed at the same 
incubation period that the energetic injury was more dramatic. Moreover, by using an in 
vivo model we observed the occurrence of an intense MTX-mediated hepatotoxicity and 
hematological disturbances. All these aspects are discussed below. 
The in vitro and in vivo models, doses/concentrations, and time of 
incubation/exposition used were adapted to study the MTX-induced cardiotoxicity. For the 
present work, it could be highlighted the fact that the results are originated from in vitro 
and in vivo studies performed in parallel with coordinated goals, generating 
complementary data regarding the advantages of each approach and trying to surpass 
their limitations. Emphasis is given to the mechanistic pathways identified by the in vitro 
studies and pharmacokinetics and biochemical studies by in vivo studies.  
IV.1. Metabolic profile of MTX: in vitro and in vivo studies 
In studies undertaken in the Manuscript I, the metabolism of MTX was simulated in 
vitro by using hepatic S9 fractions isolated from adult rats, supplemented with NADPH 
(1mM) and GSH (4mM). After a 4h incubation with MTX (100µM), the MTX content was 
35% lower than at time 0; five chromatographic peaks were identified as MTX related 
products, namely the naphtoquinoxaline metabolite, an acetoxy ester derivative (never 
described before in this model), two MTX GSH conjugates and a MTX monocarboxylic 
acid derivative (trace amounts) (Figure 5) (Manuscript I).  
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Figure 5: Proposed chemical structure of the metabolites corresponding to the five 
chromatographic peaks obtained by LC/DAD-ESI/MS analysis. Compounds were obtained 
after 4h incubation of MTX (100µM) with hepatic S9 fractions isolated from adult male rats 
pre-treated with phenobarbital (0.2% in drinking water for one week prior isolation). 
Hepatic S9 fractions (4mg/ml) were supplemented with NADPH (1mM) and GSH (4mM). 
 
The UV-VIS spectrum of the MTX obtained products showed that they retained the 
tricyclic planar chromophore group, suggesting that all compounds could have 
pharmacological interest, namely the ability to form covalent complexes with DNA (21). 
However, the only metabolite ever reported as bioactive is the naphtoquinoxaline 
metabolite (Figure 2 and Figure 5) (27,30,37,44). In fact, this metabolite was already 
described as the product of MTX metabolism through heme containing enzymes systems, 
CYP450, and peroxidases, and as an excretion product in the urine of humans and many 
laboratory animals (27,30) (Table 2). 
A novel compound was described as a MTX metabolic product (Manuscript I) 
(Figure 5) with a –COOCH3 group introduced in the MTX molecule. The pathways 
involved in the metabolite formation remain unclear, but we suggested that the acetoxy 
derivative can result from an N-oxygenation in the aromatic amine, followed by an 
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acetylation. In fact, in primary and secondary aromatic amines, N-oxygenation by CYP450 
usually results in the formation of arylhydroxylamines, which can be converted by N-
acetyltransferases (present in S9 fractions), functioning as O-acetyltransferases, to 
acetoxy esters (124). Another structural possibility for this compound is the introduction of 
the –CH2COOH group in the MTX molecule instead of the –COOCH3, which is also 
compatible with the MS spectrum; however, those metabolic routes are unlikely. 
MTX-derived GSH conjugates are known as one of the detoxifying products of MTX 
(27,32) (Table 2). The methodology employed in our study does not allow a conclusion 
about the site of GSH conjugation. Two hypotheses were considered regarding the GSH 
conjugation site, namely in the diaminobenzene and in the dihydroxybenzene part of MTX 
molecule. Initially, Blanz and co-workers described both GSH conjugates on the 
diaminophenyl part using 13C-NMR and 1H-NMR techniques. 13C-NMR data showed that 
regarding the two carbon resonances of MTX attributed to C6/C7 and C2/C3, one suffered 
a downfield shift, indicating a symmetrical substitution of two hydrogen atoms by sulfur-
containing groups. However, the location of the conjugation site remained unclear 
because the chemical shifts of these carbons were nearly equivalent. Thus, the 1H-NMR 
data suggested that the conjugation was at C6/C7 because the resonance typical for the 
protons at C6/C7 disappeared (27). However, in a subsequent investigation applying two-
dimensional 1H-13C-heteronuclear multiple-bond connectivity NMR and within the same 
group of authors, it became apparent that the S-atom of GSH was bound to C2 (37). 
Thus, it was concluded that, while the intramolecular attack of the nucleophilic side chain 
N-atom on the oxidized MTX takes place at position C6, leading to the naphtoquinoxaline 
metabolite, the corresponding reaction with external nucleophiles, such as GSH, occurs at 
the dihydroxybenzene part (Figure 6) (37). 
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Figure 6: Chemical representation of nucleophilic attack sites in the MTX molecule. The 
position 6 of MTX is the site of the intramolecular attack of the nucleophilic side chain 
resulting in the formation of the naphtoquinoxaline metabolite. The external nucleophilic 
attack is favored at position 2 and 3 of MTX molecule. 
 
Given the trace amounts of MTX monocarboxylic acid derivative, little information 
regarding its MS spectrum characteristics was obtained. However, recently, a compound 
with the same molecular ion mass was associated with oxidative metabolism of MTX, 
MTX-derivative dicyclicmonocarboxylic acid (30). Thus, we suggested that the trace 
metabolite found in our experimental conditions has the structure of the 
dicyclicmonocarboxylic acid derivative shown in the Figure 5. Its pharmacological effect 
was not tested, although, we can speculatively say that this compound is a reasonable 
candidate to elicit antitumor effect given its ionisability (30). MTX monocarboxylic acid 
derivative was already detected in rat metabolism in very low and variable levels and its 
formation was related to CYP450-catalyzed reactions (27,30,31). To the best of our 
knowledge, the formation of the monocarboxylic acid derivative from the 
napthoquinoxaline structure (as proposed here) was only related to peroxidase-catalyzed 
reactions (30). Nonetheless, CYP450 and peroxidase enzyme systems, despite differing 
in the reaction mechanisms, apparently can generate identical reaction products (30). 
In order to evaluate the in vivo MTX and napthoquinoxaline metabolite presence in 
the liver (the main metabolic organ) and heart (the main toxicity target of MTX), extracts of 
both organs were analyzed after excision from rats treated with MTX (7.5mg/kg, i.p.) 24h 
before the euthanasia. 
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In liver extracts of animals treated with MTX, it was possible to observe the 
presence of MTX and seven additional peaks when compared to the control livers; hence, 
they were assigned as MTX metabolites (Manuscript I). All the compounds absorb 
radiation in the VIS region (between 500 and 700nm), suggesting that the chromophore 
group remained intact. Due to the huge background present in the chromatograms, only 
MTX and naphtoquinoxaline metabolite, the most pharmacological relevant compound, 
were identified through UV-VIS spectrum characteristics and by the MS fragmentation. 
Although the UV-VIS spectrum does not provide an accurate identification of the 
compounds as does the MS fragmentation, an interesting discovery showed that all the 
compounds present in the liver extract of MTX-treated rats possessed a UV-VIS spectrum 
profile similar to those metabolites proposed in the above mentioned in vitro study, using 
hepatic S9 fractions. The two first peaks assigned as MTX metabolites in the liver 
chromatogram presented a maximum absorbance in the visible region set at 619nm and 
673nm, agreeing with the UV-VIS spectrum of the MTX-GSH conjugate. The next 
metabolite peak had the same absorbance profile in the visible region of the 
dicyclicnaphtoquinoxaline monocarboxylic acid derivative, namely 610nm and 658nm. The 
three remaining compounds had a UV-VIS spectrum with absorbance maximum at 610 
nm and 661nm, which are the absorbance maximum peaks of the novel metabolite 
(acetoxy ester) and MTX. These data suggest that in vivo MTX metabolites found in the 
hepatic tissue are, at least, chemically similar to those produced in vitro. 
In the heart extracts of the animals treated with MTX, only MTX and the 
naphtoquinoxaline metabolite were found in trace amounts. Both compounds were 
identified through analysis of their DAD spectrum properties and MS fragmentation 
(Manuscript I). 
The presence of MTX in heart and liver of MTX treated rats herein shown is in 
accordance with the current literature that states the broad tissue distribution profile of 
MTX (26,104). It is known that MTX is retained in these organs even one month after a 
single dose treatment (12mg/m2) in humans (1,26). However, this is the first time that the 
presence of the naphtoquinoxaline metabolite in liver and heart was described in an 
animal model. The detection of the naphtoquinoxaline metabolite in the liver and heart 
suggests that this metabolite also has the potential to be retained in highly perfused 
organs. Nonetheless, for how long this compound is found in these tissues remains 
unknown. We only evaluated the end-point of 24h after MTX treatment, which is a short 
period to evaluate MTX tissue retention profile. Even so, it might account to MTX toxicity 
observed in these organs, such as those observed in the studies performed within this 
thesis (discussed below).  
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IV.2. Influence of MTX metabolism on its (cardio)toxicity 
According to the results presented in the Manuscript I, metabolites of MTX are more 
cytotoxic than MTX in the H9c2 cells, suggesting the relevance of MTX metabolism to its 
cardiotoxicity. In fact, in the study described in the Methods section we have treatment 
groups with the extracts of the previous incubations of the supplemented S9 fractions with 
100µM MTX at time 0 (non-metabolized MTX) and after 4h (containing 35% less MTX 
than at time 0 plus the proposed metabolites presented in the Figure 5). Furthermore, the 
experimental protocol included a matrix group that did not contain MTX. Analyses of the 
extracts were performed through LC/DAD-ESI/MS, prior to the incubations with H9c2 
cells, to guarantee the identity and content of each extract. Results revealed that even 
with less amounts of MTX, the presence of the metabolites significantly increased the 
cell’s cytotoxicity, evaluated through the reduction of MTT assay after a 24h period of 
incubation, when compared to the non-metabolized MTX group. 
The complex metabolic extract containing all in vitro formed metabolites (Figure 5) is 
more cytotoxic than MTX without previous metabolism. However, the individual 
contribution of each byproduct was not determined and, as already referred, the majority 
of the proposed metabolites have unknown toxicity profiles. In fact, considering the five 
proposed metabolites, the only that has known toxicological relevance is the 
naphtoquinoxaline (34,37,125). Regarding naphtoquinoxaline-induced cardiac damage, 
Shipp and co-workers described, in 1993, a depletion of ATP levels to 67.3±6.3% of 
control after 72h of previous 3h naphtoquinoxaline (39µM) incubation in cultured neonatal 
rat cardiomyocytes. In the same study and using the same incubation conditions and cell 
model, MTX at 3.9µM, caused a depletion in the ATP levels of about 55.1±3.9% of control 
(125). These results demonstrate that, in the tested conditions, MTX has a greater effect 
on ATP levels than its metabolite since a significant lower concentration of MTX (10 fold) 
was used to obtain similar energetic effects. However, in our study, even considering that 
we did not quantified the naphtoquinoxaline levels present in the MTX+metabolites group, 
its concentration is certainly lower than MTX, since it was formed from MTX (100µM) 
incubation with supplemented S9 fractions. Obviously, this treatment group contains other 
MTX metabolites besides naphtoquinoxaline, which may account for the enhancement of 
the toxic effects even with about 35% less MTX (since MTX was biotransformed) when 
compared to MTX alone group. In fact, the enhanced cytotoxicity of MTX after the 
inhibition of epoxide hydrolase has been already described, suggesting that MTX is 
oxidized by the CYP450 oxidase mixed function to an epoxide (33). Epoxides are quite 
reactive, but none of such toxic metabolites were detected in our study; of notice epoxide 
hydrolase induction may occur by previous phenobarbital administration to the rat. 
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Additionally, it is important to refer that in the study performed by Shipp and co-workers 
the cells were incubated for only 3h, washed, the medium was replaced, and ATP levels 
were evaluated after 72h showing that the initial exposure to the metabolite or MTX was 
sufficient to elicit a toxic response. In contrast, in the study presented in this thesis, the 
incubation period was longer and continuous (24h) and the cytotoxicity was measured by 
MTT reduction assay. In both studies the energetic depletion was evident. Differences in 
the response magnitude might be related to the cell model used since Shipp used cultured 
neonatal rat cardiomyocytes. 
Another great contribution of our work was to highlight the in locu bioactivation of 
MTX mediated through CYP450 and namely CYP2E1 as a contributor to MTX cytotoxicity. 
For the first time, the partial reversion of MTX-induced cytotoxic effects by co-incubation 
with CYP450 metabolism inhibitors, and in particular of CYP2E1 inhibitor, was evidenced 
in a cardiomyoblast model. It is important to consider the relevance of the extra-hepatic 
metabolism to MTX-induced organ toxicity regarding that this drug accumulates in many 
organs (26). In the manuscript I, we demonstrated the presence of both MTX and 
naphtoquinoxaline metabolite in the liver and in the heart tissue of MTX treated rats. The 
toxic metabolites can be produced in the liver and carried to other organs and/or be 
formed in locu. The heart is an organ that express both CYP450 enzymes and NADPH 
cytochrome reductase (33). Noteworthy, CYP2E1 is markedly abundant in the heart when 
compared to other isoenzymes of that family (126), and we showed that it contributes to 
MTX cytotoxicity since by the inhibition of this isoenzyme the observed cytotoxicity was 
partially prevented (Manuscript I). 
Despite the significant protection obtained with CYP450 and CYP2E1 inhibitors, 
MTP (0.5mM) and DAS (150µM) respectively, the damage was only partially 
counteracted. This partial protection may be related to the direct toxic effect of MTX or the 
involvement of other enzymes present in the H9c2 cells that can promote the bioactivation 
of MTX. Additionally, the co-incubation of these inhibitors with MTX (100nM and 1µM) did 
not prevent the increase in the caspase-3 activity shown in the absence of metabolism 
inhibitors, favoring the participation of other metabolites or of MTX-itself to this effect 
(Manuscript II). Thus, these results suggest that CYP inhibition and the metabolites 
generated by it were not associated to apoptosis. 
In accordance with our results, in a previous study performed by co-incubating 
HepG2 cells with MTP (0.5mM) and MTX (5µM) for 4h the decrease in the cell growth was 
prevented when quantified 48h after removing these compounds, and compared to MTX 
incubation in the absence of MTP (33). Conversely, co-incubation of MTP (0.5mM) with 
MTX (10 and 200µM) for 4h partially prevented the cytotoxicity of MTX, evaluated through 
the LDH leakage assay, in the MCF7 human breast cancer cells subjected to CYP450 
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induced metabolism. Furthermore, in the same model, MTP (0.5mM) co-incubated with a 
lower concentration of MTX (10µM) for 4h counteracted the GSH depletion observed in 
the absence of the CYP450 inhibitor (36). The partial counteraction by MTP in the 
reduction of GSH levels might be related to the decreased need of GSH to detoxify the 
MTX toxic metabolites by conjugation, since the formation of those intermediary species is 
inhibited by MTP. Another possibility is that the inhibition of CYP450 leads to the 
formation of less reactive species resulting of the electron leakage of the CYP450 reaction 
by itself, thus consuming less GSH. At high MTX concentration (200µM), although the 
membrane cellular integrity was preserved by MTP (0.5mM) co-incubation, CYP450 
inhibition did not alter the intracellular GSH levels reduced by MTX incubation (36). 
Noteworthy, full protection of MTX-induced cytotoxicity was observed with the 
simultaneous incubation of MTP (1mM) and MTX at high concentrations (200 to 400µM) in 
two different hepatic cell models, namely hepatocytes isolated from male adult rats and 
HepG2 cells incubated for 4 and 9h (37). The prevention of MTX-induced cytotoxicity with 
MTP obtained by Mewes and co-workers (37) was superior of those demonstrated by us 
and by the work of Li and co-workers (36). However, it is important to refer that we cannot 
directly compare different endpoints, cell models, MTX and MTP concentrations. In fact, 
the concentration of MTP employed by Mewes and co-workers (1mM) was twice the one 
used by us and Li and co-workers (0.5mM) and our incubation period was longer (96h) 
with lower MTX concentrations. Moreover, the full vs. partial protection observed can be 
related to the differences in the parameters evaluated to measure the cell damage. 
Mewes and co-workers quantified the ultimate cell viability loss through the LDH leakage 
assay and we used the MTT reduction assay in our protective studies with metabolism 
inhibitors. At least in the H9c2 cell model, the MTT reduction assay demonstrated to be 
more sensitive to detect MTX cytotoxicity than LDH leakage test, as demonstrated by the 
time and response curves using the same MTX concentration range and incubation 
periods in the H9c2 cells (Manuscript II). This result could be explained by the nature of 
both cytotoxicity assays: the MTT reduction test is related to the cell ability to metabolize 
formazan crystals. The MTT metabolization is mostly catalyzed by mitochondrial 
dehydrogenases, thus the reduction of MTT is commonly considered as a mitochondrial 
viability index (106). On the other hand, LDH leakage assay is associated to membrane 
disruption and consequent loss of cellular integrity (127). Hence, LDH leakage assay 
usually measures irreversible damage while changes in the MTT reduction assay, as well 
as alterations in the antioxidant defenses, commonly manifest themselves earlier. Thus, it 
can explain the MTP-induced full protection observed in the LDH leakage assay and the 
absence of a protective effect considering the GSH levels observed by Li and co-workers 
with MTX high concentration (200µM) (36). 
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IV.2.1. Cytoxicity as a consequence of metabolic activation 
Traditionally, it is believed that the mechanisms of MTX cardiotoxicity involve the 
oxidative activation of its quinone group, leading to reactive species generation (36,37). 
Indeed, it was demonstrated that the incubation of MTX (1.60µM) with H9c2 cells elicits 
late increases in the peroxides production after a 16h incubation (128). However, the 
knowledge that the one-electron reduction potential of MTX does not favor the formation 
of a semi-quinone radical brought up questions concerning whether the MTX redox 
cycling has a primary role in MTX cardiotoxicity (35,59,129). Some authors defend that, 
instead of causing oxidative stress, MTX elicits antioxidant effects (1,29) since the 
inhibition of lipid peroxidation after MTX incubation was observed in many in vitro models, 
such as heart sarcosomes isolated from rabbit, mitochondria isolated from rabbit, and in 
liver microsomes isolated from rabbit (29,75). Notwithstanding the contradictory results, 
the interest in the assessment of the MTX effects among (anti)oxidative pathways still 
persists because MTX does not seem to be innocuous to the cellular antioxidant 
defenses. 
The enzymatic pathway of MTX oxidation has a strong influence in the extent and 
nature of all formed metabolites (30). For a long time, it was discussed whether MTX 
undergoes one- or two-electron reduction since this issue will be connected to the 
magnitude of oxidative stress formed as consequence of MTX bioactivation 
(32,33,35,130). The one-electron reduction yields reactive semi-quinone radicals and is 
promoted by reductases (e.g. flavin NADPH cytochrome reductases) and peroxidases 
such as myeloperoxidase (30,33,38) (Figure 7). The generated semi-quinones enter in 
deleterious redox cycling with oxygen, forming many reactive oxygen species and, 
consequently, oxidative stress, in a process similar to what is described for doxorubicin 
(33,35). The two-electron reduction is mediated by CYP450 mixed function oxidases and 
NADPH quinone acceptor oxidoreductase (also known as DT-diaphorase) and forms 
hydroquinones, which are more stable products (32,33,35,130) (Figure 7). Commonly, 
hydroquinones are rapidly eliminated from the cell, but sometimes, in the presence of 
oxygen, they enter in a redox cycle due to auto-oxidation to semiquinones and quinones, 
also generating superoxide radical anion, as represented in the Figure 7 (36). 
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One-electron reduction: 
 
Two-electron reduction: 
 
      O2 
Two consecutive one-electron reductions 
Figure 7: Schematic representation of one-electron and two-electron reduction of 
anthraquinones. The one-electron reduction involves the formation of semi-quinone 
radicals that can enter into redox cycling. Two-electron reduction generates 
hydroquinones, which can be detoxified or suffer auto-oxidation (two consecutive one-
electron reductions). Adapted from (36,130). 
 
Regarding MTX metabolism, the two-electron reduction is considered the 
preferential pathway, as evidenced by the prevention of the MTX bioactivation with 
CYP450-mediated metabolism inhibition (33,36,37), which was also observed by us 
(Manuscript I). One product of the two-electron reduction is the naphtoquinoxaline 
metabolite. However, studies demonstrate that MTX can also be metabolized by 
peroxidases in two steps of one-electron reductions to naphtoquinoxaline metabolite, 
which may contribute to the great effectiveness of MTX in the treatment of solid tumors 
containing high peroxidase secretion capacity (30,34,38). Thus, soluble 
peroxidase/hydrogen peroxide systems present in the extracellular spaces of solid tumors, 
such as lymphoma, breast, and prostate cancer can oxidize MTX and the consequent 
acidic oxidation products may accumulate in the neutral intra-cellular compartments, 
binding to cell targets and increasing MTX cytotoxicity (30). 
The naphtoquinoxaline metabolite formation has been reported through the action of 
CYP450s, DT-diaphorase, NADPH cytochrome reductases, and peroxidases, however it 
is plausible that the naphtoquinoxaline detected in urine samples of MTX patients is 
primary derived from CYP450 oxidation, since it is the main oxidoreductive pathway (30). 
The formation of naphtoquinoxaline involves the abstraction of two electrons. Thus, when 
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suffering one-electron reduction, the naphtoquinoxaline formation might be due to two 
consecutive one-electron abstractions, the second one removed via enzyme interaction 
with MTX radicals or from enzyme-independent radical disprotonation process (30). 
Moreover, as already mentioned, the reduction of MTX by flavin-reductases is not easy 
due to its low one-electron reduction potential (35). Additionally, oxidation by peroxidases 
is strongly dependent on hydrogen peroxide availability (30). The availability of NADPH is 
also crucial, as shown in a study using isolated human liver NADPH CYP450 reductase, 
since the reductive activation of MTX was demonstrated only in the presence of high 
amounts of NADPH (500µM) (28). While incubation of MTX (100µM) in the presence of 
isolated NADPH-cytochrome reductase increased the rate of NADPH oxidation about 20 
fold, using a more complex system such as rabbit hepatic microsomes, MTX incubation 
did not stimulate the basal oxidation of NADPH (29), corroborating the difficulty of MTX 
undergoing one-electron reduction in non-isolated enzyme systems. 
In order to evaluate the role of the metabolic enzymes in MTX-induced cytotoxicity, 
Li and co-workers did a study in 1995 using the MCF7 cell model and cells were pre-
treated with 1,2-benzanthracene (25µM) for three days. Pre-treatment with 1,2-
benzanthrecene induced by 64- and 1.6-fold the activities of CYP450 and DT-diaphorase, 
respectively. An increase of MTX-induced cytotoxicity, evaluated through the LDH leakage 
assay, was related to a decrease in the GSH and protein contents after pre-treatment with 
1,2-benzanthrecene. Even in the cells that had a high increase in CYP450 activity, the co-
incubation of MTX (10µM) with the CYP450 inhibitor MTP (0.5mM) for 4h prevented the 
GSH depletion and reduced the LDH leakage, when comparing to the results observed in 
the absence of MTP (MTX concentrations of 10µM and 200µM). Moreover, co-incubation 
of MTX and dicoumarol (an inhibitor of DT-diaphorase) (30µM) for 4h prevented the MTX 
deleterious effects upon GSH levels in all the MTX treated groups (10, 100, and 200µM), 
in the protein content in 100 and 200µM MTX, and in the LDH leakage assay only in the 
lower MTX concentration tested (10µM). These results show the importance of the two-
electron reduction in MTX bioactivation and its involvement in MTX cytotoxicity and 
impairment of oxidative stress defenses. In the same cell model, pre-treatment with 
dexamethasone (1µM) elicited a small but significant increase in the NADPH cytochrome 
c reductase activity. This increased activity of NADPH cytochrome c reductase had no 
effect on MTX-induced cytotoxicity, evidencing, once more, that the one-electron 
reduction does not seem to be relevant for MTX cytotoxicity (36). However, in a study 
using HepG2 cells by Duthie and co-workers in 1989, no protective effect in GSH levels 
was observed by the incubation of MTX (100µM) with dicoumarol (30µM) (33). Moreover, 
dicoumarol potentiated the cytotoxicity observed with MTX, evaluated by the LDH leakage 
assay (33). These results contradict the results demonstrated by Li and co-workers (36), 
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probably due to the use of different cell models with dissimilar metabolic competence 
(HepG2 cells vs. MCF7 cells). 
IV.2.2. MTX-induced oxidative stress and its (cardio)toxicity 
Oxidative stress appears to be an important component to the toxicity mechanisms 
of several xenobiotics, which contain or can be biotransformed into a quinone (124,131). 
Actually, oxidative stress is commonly referred as a key factor for the intrinsic 
cardiotoxicity elicited by catecholamines (118,132) and the cardiotoxic effects of 
antineoplastic agents such as doxorubicin and daunorubicin (58,133,134). Since the 
cardiotoxicity of MTX is clinically similar to that observed with doxorubicin, it was believed 
that these drugs also shared the mechanisms involved in the late cardiac disease (102). 
Hence, the possibility that oxidative stress exerts a leading role in the MTX-induced 
cardiotoxicity has been considered and largely investigated (49,125,129,130,135). 
The cardiac tissue is particularly susceptible to oxidative stress when compared to 
other organs due to its limited antioxidant defenses (136). Cardiac GSH levels and 
antioxidant enzymes, namely catalase, superoxide dismutase, and glutathione peroxidase 
are less abundant in the cardiac tissue than in the liver (137,138). Even so, paradoxically, 
the heart generates higher levels of hydrogen peroxide than other organs (139) and it may 
contribute to its vulnerability to drug-induced oxidative imbalance. It is known that there is 
a significant positive correlation between the metabolism of most quinone(di)imines and 
the generation of superoxide anion radical, which makes the heart a target to drugs 
containing these chemical structures, such as MTX (124,130,131). Another feature that 
aggravates the consequences of drug-induced cardiotoxicity is the modest regenerative 
ability of the heart. Nowadays, it is known that cardiac cells present a limited capacity for 
myocardial regeneration, although it is commonly insufficient to restore normal heart 
function after cardiac injury (140). 
Besides the above oxidative stress thesis for MTX-induced cardiotoxicity, the results 
compiled in Manuscript II and the glutathione status evaluated in MTX treated heart 
presented in the Manuscript III are consistent with the old thesis of Butler and co-workers 
that MTX metabolism is expected to produce few, if any, reactive species (130). The 
controversy of these results will be discussed in the following paragraphs in order to clarify 
the different perspectives and studies related with the formation of reactive species, lipid 
peroxidation, GSH content, and the use of antioxidants as NAC or of iron chelators. 
Low levels of reactive species formation were observed with some 
quinone(di)imines, such as indophenol, N,N-dimethylindolaniline, 2,3’6-trichloroindophenol 
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trifluoracetate, and N,N’-dichloro-2-chloro-1,4-benzoquinonediimine, and apparently, MTX. 
These compounds undergo rapid metabolism, forming little or no detectable reactive 
species (131). Moreover, as already referred, the oxidoreductive reactions involved in the 
MTX metabolism favor the formation of hydroquinones instead of semi-quinones 
(33,36,37). Hence, there is a minor formation of reactive species directly associated with 
this metabolism in comparison with those generated by quinone/semi-quinone redox 
cycling (130). Even so, the auto-oxidation of hydroquinones can also lead to some 
reactive species generation (36). The studies conducted in the H9c2 cells (Manuscript II) 
suggested that the oxidative stress might not be the primary cause of the MTX 
cytotoxicity, since the evaluation of several markers of oxidative stress showed that they 
remained largely unchanged.  
Regarding lipid peroxidation, we did not observe any significant changes in the 
malondialdehyde levels after incubation with MTX (100nM and 1µM) in H9c2 cells at any 
time point tested (24, 48, or 96h) in comparison with control levels (Manuscript II). This 
finding is in accordance with the results obtained in heart homogenates from MTX treated 
mice (15mg/kg, i.p.) evaluated two and five days after MTX single dose (59). Surprisingly, 
MTX in vitro was already associated with the inhibition of lipid peroxidation. In fact, in liver 
microsomes, heart sarcosomes, and mitochondria isolated from rabbit incubated with 
MTX (50, 100, and 200µM), the rate of lipid peroxidation was significant lower than that 
observed in controls (29,75). Moreover, besides inhibiting the endogenous lipid 
peroxidation, it has been demonstrated that MTX incubation at micro molar levels inhibited 
doxorubicin induced lipid peroxidation, ferric ion- and ADP ferric ion-mediated lipid 
peroxidation (29). The mechanisms involved in these inhibitory effects on lipid 
peroxidation remain mainly unknown: it has been suggested, however, that MTX can 
modify oxidative homeostasis. Data suggest that MTX-inhibition of lipid peroxidation is not 
related to the lower formation of superoxide radical anion since the inhibition of 
doxorubicin-induced microsomal superoxide generation is only reached with higher MTX 
concentrations than those required to inhibit the lipid peroxidation (29,75). Furthermore, 
MTX weakly complexes iron, which is involved in the initiation/propagation of lipid 
peroxidation (75). Hence, authors suggest that the MTX-inhibition of lipid peroxidation 
occurs at a mechanistic step subsequent to the enzymatic generation of superoxide and 
cannot be attributed to any of MTX iron chelation abilities (75).  
Alterations in the oxidative stress parameters, namely increase in the reactive 
species and decrease in the GSH intracellular levels, were found only in the last time-
point evaluated in the H9c2 cell model. In fact, after 96h incubation with MTX, both 
working concentrations (100nM and 1µM) caused a significant increase in the reactive 
species (Manuscript II), evidencing that this effect is a late event, since it did not occur in 
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any of earlier time points tested (1h to 10h incubation). The modest potential to generate 
reactive species in short incubation periods was also demonstrated in MCF7 S9 fractions, 
where a very low superoxide anion generation was observed after 30min incubation with 
MTX (100µM) and no hydroxyl radical or semiquinone formation was detected after 
incubation with MTX (even with the high concentration of 400µM) (35,129). Incubation of 
MTX (100µM) in the presence of NADPH-cytochrome reductase increased superoxide 
and hydrogen peroxide generation about 20-fold, however this was considered a slight 
increase when compared to structural analogues. Furthermore, using more complex 
systems such as rabbit hepatic microsomes, MTX incubation did not stimulate any 
detectable superoxide formation (29), suggesting that this pro-oxidant potential is only 
reached with isolated enzymes. Nevertheless, in the H9c2 cells after a 16h incubation with 
MTX (1.60µM), peroxide production increased (128). In the results presented in the 
Manuscript II, we detected increases in reactive species generation after 96h of MTX 
incubation (100nM and 1µM). These results corroborate the suggested hypothesis that the 
oxidative imbalance eventually associated with MTX is secondary to another initial toxic 
mechanism. Considering in vivo studies, mice treated with a single dose of MTX 
(15mg/kg, i.p.) did not present any cardiac significant changes in the hydroperoxide-
initiated chemiluminescence, after two to five days (59). 
After 96h incubation with MTX at the lower working concentration (100nM), a slight 
but significant decline in the GSHt and GSH levels was observed (Manuscript II), without 
any change in the GSSG levels. One hypothesis that could explain this finding is that the 
GSSG formed can be extruded by multidrug resistance proteins for the extracellular 
medium, since the GSSG efflux is a cellular response aiming to protect the cells from 
oxidative stress (108,141). Another possibility is that GSH levels are diminished due to 
conjugation with either MTX or its metabolites. The later hypothesis should be regarded 
as plausible, since the conjugation of MTX metabolites with GSH is described as one of 
the main detoxifying pathway of MTX (36).  
In our study, decrease of intracellular GSH content was not observed for 1µM of 
MTX, even considering that similar levels of reactive species were generated when 
compared to MTX 100nM group, at 96h incubation (Manuscript II). One possible 
explanation is that GSH levels already recovered at 96h of 1µM MTX incubation by GSH 
synthesis. Another hypothesis is that MTX elicited a concentration biphasic decrease in 
the GSHt in vitro. The biphasic effect of MTX upon GSHt levels was already demonstrated 
in another cardiac cell model (HL-1 cells), where after 24h, the incubation of MTX (1µM) 
increased the GSHt levels compared to control cells and the higher concentration (10µM) 
did not affect GSHt levels in the same incubation conditions (142). At a longer incubation 
period (48h), while the values of intracellular GSHt levels remained similar to control with 
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the lower MTX concentration of 1µM, at 10µM MTX incubation elicited a significant 
decrease in the GSHt levels (142). Regarding in vivo results obtained in the scope of 
Manuscript III, no significant changes were observed in the cardiac glutathione levels 
(GSHt, GSH, and GSSG) in none of the treated animals (MTX22 or MTX48). Conversely, 
cardiac GSH levels were not affected by MTX treatment (15mg/kg, i.p.), in mice that 
suffered euthanasia 2-5 days after MTX administration (59) and cardiac GSH content, 
glutathione peroxidase, catalase and superoxide dismutase activities were not altered in 
female BALB/c mice weekly treated with MTX (0.2mg/kg, i.p.) over 12 weeks and suffered 
euthanasia one week after the last treatment (50). 
The use of NAC (1mM) failed to prevent the cytotoxicity elicited by MTX (100nM and 
1µM) after 96h incubation with H9c2 cells (Manuscript II), evaluated through the MTT 
reduction assay. NAC is a powerful scavenger of reactive species and it improves the 
GSH synthesis (143). Because of these properties, NAC has been shown to be effective 
in protecting cells when oxidative stress conditions are imperative (113,114,127). 
However, the only cytotoxic parameter evaluated by using this protective study was the 
reduction of MTT evaluated only at 96h. Thus, it should not be excluded that NAC might 
ameliorate the oxidative stress altered parameters, such as late reactive species 
generation or GSH decrease in the MTX 100nM group (143). Even so, in case that 
protection occurred, it was not enough to prevent cellular damage, again suggesting that 
oxidative stress does not occupy a leading role in the MTX-mediated cytotoxicity.  
Contradictory results exist regarding the protective effects elicited by ICRF-187, an 
iron chelator, in the MTX-induced toxic effects. The aim of using ICRF-187 is to block the 
iron-stimulated free radical formation via Fenton reaction (144). In MTX-treated isolated 
neonatal rat cardiomyocytes, the incubation with ICRF-187 (50µg/ml) elicited a partial 
cytoprotection when continuous incubated 3h before, during, and 72h after previous MTX 
(2µg/ml) 3h incubation, as evaluated through the ATP measurement. However, regarding 
3h co-incubation of MTX and ICRF-187 (without ICRF-187 pre-treatment or post treatment 
but using the same concentrations), this regimen was not effective in protecting the cells 
against MTX-induced cell damage on ATP levels (125). Thus, the cellular protection was 
probably dependent on the time of ICRF-187 incubation. Moreover, ICRF-187 
administered 5min before MTX, (at doses 20 times higher than MTX dose) delayed the 
MTX-induced death on CD-1 mice receiving MTX (twice weekly, at doses 2mg/kg and 
4mg/kg, treated on weeks one, two, and five and suffered euthanasia on the week seven) 
(125), corroborating the cardioprotective effect shown in vitro (125). Despite the 
cardioprotection demonstrated in vitro and in vivo, ICRF-187 did not affect the MTX 
antitumor action in the L1210 cell line (a mouse leukemia cell model) and in a DBA/2J 
mice bearing P-388 leukemia (125), which suggested that the mechanisms involved in the 
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MTX-antitumor action and MTX-induced cardiotoxicity are diverse. In contrast with the 
good results obtained by Shipp and co-workers, female BALB/c mice weekly treated with 
ICRF-187 (12.5mg/kg, 30min prior to MTX) and MTX (0.2mg/kg) over 12 weeks, suffered 
euthanasia one week after the last treatment, did not present significant changes in the 
cardiac parameters evaluated (morphological changes evaluated through light and 
electron microscopy) compared to mice that did not receive ICRF-187 (50). The 
mismatched results may arise from differences in MTX doses and regimen administration, 
namely the duration of treatment. Even so, the partial protective effects of ICRF-187 in 
vitro and in vivo suggest that divalent metal ions, such as iron, can be partially involved in 
the MTX-cardiotoxicity (125), not necessarily through iron-mediated oxidative stress. 
Moreover, we cannot exclude the possibility that the partial protection observed is due to 
another intracellular mechanism of ICRF-187, which is not yet elucidated.  
Despite the majority of negative results in cardiac models, oxidative stress seems to 
assume a more pronounced role in other target organs such as the liver. The MTX-
induced hepatic damage evidenced in the study presented in the Manuscript IV, for 
example, was associated with increases in the hepatic levels of GSHt observed in the 
MTX48 group. This increase was related to a slight (but significant) increase in the GSH 
hepatic levels and to a notorious increase in the GSSG levels. Increases in GSH might be 
interpreted as an attempt to enhance the antioxidant content in order to counteract the 
inflicted injury, while increased levels of GSSG are related with oxidative stress. It is 
known that Kupffer cells, which were abundantly present in the MTX48 livers (Manuscript 
IV), are a source of reactive species (145). The link between oxidative stress and the 
MTX-induced hepatic damage was already suggested in a study with mice, where a single 
administration of MTX (15mg/kg) caused increases in the hepatic lipid peroxidation, 
decreases in the antioxidant enzymes activities (superoxide dismutase, catalase, and 
glutathione peroxidase), and depletion of hepatic retinol and GSH levels (49). Moreover, 
the incubation of MTX (100µM) with HepG2 cells for 6h was enough to promote the 
decrease in the GSH levels (33). The apparent contradiction between our results 
(increase in the GSH hepatic levels) and the previously reported data (decreases in the 
GSH content) may be explained by the differences in the experimental design and model. 
The quoted studies assess in vivo the liver GSH levels three, four, and five days after 
MTX administration (49) or 6h after high concentration incubation of cells with MTX (33). 
In the present study, the significant changes in the glutathione status were a late event, 
only observed 28 days after the last cycle of a cumulative dose administration regimen. 
Hence, the organism is probably subjected to compensatory effects, in order to counteract 
the increase in the hepatic GSSG levels and this adaptive phenomenon is favored by the 
long time between last MTX administration and rat euthanasia. Another evidence of MTX-
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potential oxidative stress on the liver, in particular in human liver microsomes incubated in 
anaerobic conditions with MTX (50µM), is the increased formation of reactive species 
detected through electron spin resonance analysis (135). 
We hypothesize that the different propensity to oxidative stress in different tissues 
might be related to organ metabolic competence. The enzymatic availability in the liver is 
much higher than in the heart. Therefore it is possible that in other systems with a smaller 
amount of enzymes available, such as heart, the oxidative stress is not a primary cause of 
damage, because MTX one reduction potential is very low (527± 5 mV) (35). In contrast, 
in an enzymatic abundant environment, the extent of MTX suffering oxidative activation 
(and, therefore, producing reactive intermediates) is higher, and despite the preference for 
two-electron reduction pathway, a minor extent (but higher than in another organs 
enzymatically poorer) might undergo to one-electron reduction.  
IV.3. Calcium regulation, mitochondrial membrane potential and cell 
death 
The role of calcium on cell physiology goes from cell signaling to cell death (146). 
Normally, intracellular calcium levels are tightly regulated between the range of 10-100nM 
by ionic channels and transporters, energy-dependent pumps, and organelles that uptake 
and buffer this ion (147–149) (Figure 9). The first calcium barrier is the plasma membrane, 
which mediates the calcium influx by ligand-gated and voltage-channels in order to 
maintain a large calcium gradient across the membrane (149). The endoplasmic reticulum 
is the largest reservoir of calcium in cardiomyocytes, having concentrations that can reach 
the milimolar levels (148,149). Furthermore, mitochondria perform the function of buffering 
intracellular calcium. The influx of calcium into the mitochondrial matrix is dependent on 
the membrane electrochemical potential, which is maintained by mitochondrial respiration, 
and by a low resting intra- mitochondrial calcium concentration, which is maintained 
primarily by the mitochondrial sodium/calcium exchanger (146). 
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Figure 8: Mechanisms of elimination and maintenance of calcium cytosolic levels. (A) 
Calcium ATPase-mediated pumping into the extracellular space, (B) ion-gradient driven 
transport into the extracellular space by the sodium/calcium exchanger, (C) ion-gradient 
driven transport into mitochondria by calcium uniporter, and (D) ATPase-mediated 
transport into the endoplasmic reticulum. Adapted from (148). 
 
Intracellular calcium levels rise when calcium flux into the cell is increased, following 
the energetic impairment and/or in conditions that modify the release or uptake of calcium 
from the endoplasmic reticulum and/or mitochondria (147). As a consequence, elevated 
intracellular calcium levels may activate hydrolytic enzymes, such as phospholipases, 
endonucleases, and proteases, resulting in the modification of the permeability of the 
membranes and degradation of intracellular structures (146–148). Moreover, calcium 
overload may elicit the depletion of energy reserves, the dysfunction in microfilaments and 
the generation of reactive species (148). Hence, the calcium hypothesis is based on the 
observation that pathological increases in the intracellular calcium lead to degenerative 
events that can be avoided if those increases are prevented (146). 
A sustained increase in the intracellular calcium precede cellular pre-lethal and 
lethal changes (147). It is known that calcium overload can trigger both cell death forms: 
necrosis and apoptosis (146). The cell death mechanisms are discussed in more detail 
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below, but calcium increases have an important role on caspase activation and 
consequent apoptosis (149). 
In the in vitro study presented in the Manuscript II, MTX incubation with H9c2 cells 
led to increased calcium intracellular levels with concomitant increase in the mitochondrial 
membrane potential. A close relationship between the mitochondrial membrane potential 
and calcium intracellular levels is well known, since the regulation of calcium 
mitochondrial levels is mediated through the calcium uniporter using the mitochondrial 
membrane potential as driving force (148,150). The retention of mitochondrial membrane 
potential during calcium increase favors mitochondrial calcium uptake and overload, 
resulting in cell death, normally by apoptosis (149). The mitochondrial calcium overload 
secondary to a cytoplasmic calcium overload may trigger the mitochondrial permeability 
transition pore (MPT) (149). Although a low conductance state of the pore is reversible, 
sustained transitions dissipate the mitochondrial membrane potential, impairing ATP 
synthesis, leading to the release of cytochrome c and, consequently, initiation of apoptosis 
(148,149,151). The increase in mitochondrial membrane potential is observed in 
pathological conditions, such as ischemic cardiomyocytes during reperfusion. In ischemic 
conditions, cardiac mitochondria are energized and permit calcium uptake and 
mitochondrial damage. During reperfusion, the mitochondrial membrane potential 
increases in order to allow the respiration, lethally damaging other organelles by cytosolic 
increases of calcium (149). Other examples of increased mitochondrial membrane 
potential occurred in mitochondrial vascular endothelial cells subjected to pulsatile shear 
stress (152), and physiologically during pre-implantation stages of human and mouse 
embryo development, in response of metabolic demand (153). The hyperpolarization of 
mitochondrial membrane potential sometimes can precede the mitochondrial collapse 
and, consequently, cell death (154). 
The chronology of the calcium impairment-induced lesion also can be opposite, e.g., 
a direct lesion in the mitochondria or injuries affecting the energetic metabolism can affect 
calcium regulation since the cellular mechanisms involved in calcium handling are ATP 
dependent. Thus, at low energetic levels, calcium pumping activity decreases, resulting in 
cytosolic calcium increase (149) ultimately driving the cell to the “no return point”, leading 
to cell death (147). In our work, we observed an important energetic depletion caused by 
MTX in vitro and in vivo and signs of mitochondrial toxicity. However, it was not yet 
possible to conclude if the calcium overload is a cause or a consequence of that 
mitochondrial lesion. 
In contrast to our present work, a study of Kluza and co-workers in 2004, also with 
the H9c2 cells and using similar MTX concentrations and incubation periods (1.60µM for 
24h), showed a decrease in the mitochondrial membrane potential (128). In fact, in our 
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study, 24h incubation with 100nM and 1µM MTX caused an increase and no alteration in 
the mitochondrial membrane potential, respectively. Considering that we used the same 
cell model and similar MTX concentrations, it is possible that a slight increment in MTX 
concentration (1.60µM instead of 1µM) is enough to promote a different cellular response, 
namely the loss of the mitochondrial membrane potential. Also in the study performed by 
Kluza and co-workers, the MTX concentration of 1.60µM was defined as the mean lethal 
concentration (LC50) at 24h incubation, evaluated through the trypan blue exclusion test. 
In our cytotoxicity studies the LD50 at 24h was about between 10 and 50µM (in the LDH 
leakage assay) and 5 and 10µM (in the MTT reduction test). The discrepancy between our 
results and those presented by Kluza and co-workers might be explained through the 
nature of the cytotoxicity tests used (trypan blue exclusion assay vs. LDH leakage assay 
and MTT reduction test). Moreover, in the protocol performed by Kluza, they employed a 
trypsinization step before the trypan blue exclusion assay, which may have contributed to 
the apparent higher cytotoxic effects observed since the cells were already fragile due to 
the previous incubation with MTX. Furthermore, another data that could help to 
understand these differences is the working number of passages of H9c2 cells, however, 
this information was not available in the manuscript by Kluza. Notwithstanding, in the 
same study, the 24h incubation of MTX (1.60µM) with MTLn3 mammary adenocarcinoma 
cells caused a significant decrease in the aggregation of JC-1 probe, which the authors 
attribute to an increase in the mitochondrial mass (128). It could be an adaptive 
phenomenon, since mitochondria play a significant role in the calcium-dependent cell 
signaling by acting as a buffer of cytosolic calcium excess (98,146,155). 
IV.4. MTX-induced cell death 
Cell death is a normal phenomenon occurring during developmental stages and also 
in adult life, allowing the cells’ turnover (147). Typically, cell death can be divided in two 
modes: necrosis, generally seen as an uncontrolled process, and apoptosis, a 
programmed manner of cell death (148). Additionally, there is cell-death by autophagy, 
which is characterized by the sequestration of cytoplasmic material within 
autophagosomes prior to degradation and occurs without chromatin condensation but with 
massive autophagic vacuolization of the cytoplasm (156). 
During early stages of necrosis, cell can present alterations in compartment volume, 
e.g. swelling and rupture of endoplasmic reticulum or mitochondria, cytoplasmic blebbing, 
chromatin condensation, and eventually, cell membrane disruption (147,157). Based on 
the morphologic features of necrosis, it has been considered as an unregulated or 
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accidental fate (158). Recently, however, this view is under debate and it is considered 
that some types of necrotic death may be regulated (158). Thus, a new concept emerged: 
the necroptosis or aponecrosis, a cell-death process that shares the morphologic features 
of necrosis but is highly regulated, like apoptosis (159). 
Apoptosis occurs during development, aging, and even to allow the normal cell 
renewal, functioning as a homeostatic control of cell population (157). Morphologically, 
comparing to necrosis, the apoptotic cells typically shrink rather than swell, the nuclear 
chromatin condensation is more pronounced (pyknosis), and the cytoplasmic blebs 
usually contain organelles such as mitochondria (147). Afterwards, when the nuclear and 
cytoplasmic content are condensed, it breaks into membrane-bound fragments named 
apoptotic bodies that are phagocytized (148).  
Cells can trigger apoptotic death through different pathways that are linked and can 
mutually influence each other (157). Additionally to the intrinsic and extrinsic pathways, 
there is an additional caspase dependent pathway that involves T-cell mediated 
cytotoxicity and perforin-granzyme-dependent killing of the cell (Figure 8). Caspases are 
cysteine proteases, mostly located in the cytoplasm in their inactive forms (procaspases). 
When caspases are activated, they cleave structural proteins, especially in specific 
aspartate residues sites (148) (Figure 8). 
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Figure 9: Schematic representation of the energetic-dependent cascade of events leading 
to diverse apoptotic pathways. Each pathway activates its own procaspase, which will 
converge to caspase-3 activation (with the exception of granzyme A via that is caspase-
independent). Caspase-3 activation results in other procaspases activation (procaspase 6 
and 7) and, finally, leads to morphological and biochemical features of apoptosis. Adapted 
from (148,157). 
 
The intrinsic pathway involves mitochondria and is independent of receptor-
mediated stimuli (148,157) (Figure 8). The cytotoxic stimuli provoke changes in the inner 
mitochondrial membrane that results in the opening of MPT. It induces loss of the 
mitochondrial transmembrane potential and release of pro-apoptotic proteins, such as 
cytochrome c, Smac/DIABLO, and HtrA2/Omi into cytosol, which, consequently, activate 
the caspase-dependent mitochondrial pathway (157) (Figure 8). Caspase-9 is activated 
through the formation of the apoptosome, which consists in seven heterodimers of 
apoptotic protease activating factor-1 (Apaf-1), joined with cytochrome c that form a 
symmetrical “wheel”, which binds to procaspase-9 and promotes its activation (160). 
Thus, caspase-3 is sequentially activated by caspase-9 (148). 
The extrinsic pathway is related to cell surface death receptors (158). The ligands 
bind to their respective cell death receptor, normally members of the tumor necrosis factor 
receptor gene family (157). Subsequently, a trimerization of the receptor and the 
recruitment of adapter molecules and procaspases to the cytoplasmic tail of the receptor 
occur (148). Then, the death-inducing signaling complex (DISC) is formed and results in 
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the auto-catalytic activation of caspase-8, subsequently triggering to execution phase of 
apoptosis, also with caspase 3 activation (157).  
The perforin-granzyme-dependent pathway involves immunocytotoxicity mediated 
through T-cells that exert their cytotoxic effects on tumor cells and virus-infected cells via 
the secretion of perforin (a transmembrane pore-forming molecule) and release of 
cytoplasmic granules (granzymes) through the pore and into the target cell (157,161). As 
shown in the Figure 8, the granzyme B activates caspase-10, while granzyme A induces 
apoptosis through caspase independent pathways (157).  
Caspase-3 is seen as a key executioner to apoptosis, considering that the extrinsic 
and intrinsic pathways converge to its activation (107). In fact, execution caspases 
(caspase-3, caspase-6, and caspase-7) activate cytoplasmic endonucleases and 
proteases that degrade nuclear material and nuclear/cytoskeletal proteins, ultimately 
leading to irreversible death of the cell (157,160). 
Knowing the main cell death mechanisms, it is interesting to observe that the 
mechanisms underlying cell death induced by MTX are described as bimodal: apoptosis 
at lower concentrations and necrosis at higher concentrations (15). As already stated, in 
the present in vitro studies we used MTX working concentrations clinically relevant given 
the plasma and tissue levels of MTX (14,26). Noteworthy, we observed a time- and 
concentration- dependent cytotoxicity, being the effects more pronounced in the MTT 
reduction assay rather than in the LDH leakage assay (related to cell membrane 
disruption) in all time-points tested. At 24h incubation, only the high concentration of 50µM 
caused a loss of viability higher than 50% in the LDH leakage assay. Even after 96h 
incubation with MTX (100nM and 1µM), the majority of cells maintained their cellular 
membrane integrity, which means that we are not predominantly working in a necrotic field 
with those concentrations (Manuscript II). At higher concentrations, namely more than 
5µM, the results in the LDH leakage assay start to be more expressive at 48 and 72h 
incubation (in the range of 50-60% of viability), being extensive at 96h MTX incubation 
(maintaining only about 25% of total cell viability). These data suggest that the MTX-
induced damage into the cellular metabolic competence is prior to the loss of cellular 
membrane integrity. 
Considering the death mechanisms, we showed that MTX (100nM and 1µM) elicited 
an increase in the caspase-3 activity after 24h incubation in H9c2 cells (Manuscript II). 
These results are in accordance with previously reported characteristic signals of 
apoptosis (appearance of hypoploid DNA content, cytoplasm and chromatin 
condensation) after 24h incubation in the H9c2 cells with MTX (1.60µM) (128). After 48h 
incubation of MTX (1.60µM) in H9c2 cells, features of late phase of apoptosis, such as 
nuclear disintegration and apoptotic bodies formation, can be observed (128). Recently, 
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the evaluation of caspase-9, caspase-8, and caspase-3 activities after MTX incubation 
with the HL-1 cell model demonstrated that after 24h incubation, MTX (1µM and 10µM) 
promoted significant activity increases in all caspase subtypes tested (142). Thus, it was 
not possible to indicate one preferential pathway of MTX-induced apoptosis, suggesting 
that MTX can promote intrinsic- and extrinsic-mediated apoptosis. In the same study, after 
48h incubation, no changes were observed in caspase 3, caspase-8, and caspase-9 
activities compared to control cells (142), being in accordance with our pilot studies. When 
we evaluated the caspase-3 activity after longer incubation periods (48h and 96h) in H9c2 
cells (data not shown), no significant differences were observed, suggesting that caspase 
cascade activation is an earlier effect.  
Despite the partial protection towards MTX cytotoxicity (at 100nM and 1µM) after 
96h with the co-incubation with the CYP450 inhibitor MTP (0.5mM) or with the CYP2E1 
inhibitor DAS (150µM) (Manuscript I), the co-incubation with these metabolism inhibitors 
did not prevent the increase in the caspase-3 activity promoted by MTX incubation at 24h. 
Thus, the previous partial protection obtained with the metabolism inhibitors is not 
associated with apoptosis prevention. 
IV.5. Energetic imbalance as a protagonist of MTX-induced cardiotoxicity 
Besides the sustained rise in intracellular calcium levels, another critical biochemical 
disorder that may lead to cell death is ATP depletion. ATP is the major source of energy in 
the cardiac tissue (162,163). In fact, ATP plays a pivotal role in cellular maintenance, 
since it is utilized in biosynthetic reactions, incorporated into co-factors and nucleic acids, 
required for muscle contraction, cellular motility, cell division, vesicular transport, and even 
for the maintenance of ionic homeostasis and cell morphology (148). In healthy hearts, 
ATP levels are maintained constant. Despite studies regarding failing hearts have not 
reached a consensus, some reports found decreased levels of ATP in human failing 
hearts and that loss has been correlated with the degree of cardiac impairment (164,165).  
Due to the importance of energy supply for the muscular function, there is another 
important muscle energetic reserve system: the phosphocreatine (PCr), which is present 
in the heart at twice the ATP cardiac concentration (162). The reaction catalyzed by the 
enzyme CK transfers the phosphoryl group from ATP to creatine, forming PCr (Figure 10) 
at a rate about ten times faster than the rate of ATP synthesis. There are 3 major CK 
enzyme subtypes identified: CK-MM is the principal form in skeletal muscle, CK-BB is the 
predominant form in the brain and the kidney, and CK-MB is the main subtype in the 
myocardium, although CK-MM is also found in the heart (162). PCr is considered an 
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energetic source of rapid demand and when ATP use exceeds ATP supply, the use of 
PCr is a major pathway of energy (162). The total creatine pool is about 60 % lower in 
failing hearts, while CK levels are relatively abundant in this condition (163). Thus, a lower 
total creatine pool means that PCr must also be lower (163).  
 
 
 
 
 
Figure 10: Schematic representation of PCr mobilization. PCr is an energetic reserve 
that, through CK catalyzed-reaction, produces creatine and ATP. 
 
In the present work, decreased levels of ATP were observed in both in vitro 
myoblasts incubated with MTX and ex vivo in the heart from MTX-treated rats 
(Manuscripts II and III, respectively). In the H9c2 cells, the decrease in the ATP 
intracellular content was evident in all time points tested (24, 48, and 96h), in both MTX 
working concentrations (100nM and 1µM) and it preceded the declines in the ATP-
synthase expression and activity (Manuscript II). In the in vivo study, significant decreases 
in cardiac ATP levels were only seen in the late endpoint (MTX48 group), demonstrating 
that this effect is a late response. Significant decreased levels of ATP were already 
demonstrated as a late event (72h after pre-incubation) in cultured neonatal rat cardiac 
cells pre-incubated with MTX (about 0.1µM - 10µM for 3h) (125). Failing human hearts 
have about 25-40% less ATP than healthy hearts and the heart in energetic starvation 
fails to support an increase in the workload (163,165). Thus, the length of time that the 
heart can survive with such ATP depletion still remains unclear (163), and speculatively 
could help to explain the two deaths observed in the MTX48 group (Manuscript III). 
It has been described that the loss of ATP in the failing myocardium is a slow and 
progressive phenomenon, only detectable when the heart is in severe failure (163), which 
is in agreement with our in vivo results. The sequence of events in the establishment of a 
failing and energy starved heart are: the decrease in the PCr levels followed by the loss in 
the creatine levels and, ultimately, ATP depletion (163). Decreases in the plasma total CK 
activity and CK-MB levels were observed in the MTX22 group (Manuscript III) and may be 
interpreted as a hallmark of the development of the heart failure (136). However, signaling 
pathways involved in CK alterations remain to be elucidated (136). Even so, it has been 
reported a decreased CK activity in heart mitochondria isolated from MTX treated female 
rats (1mg/kg, twice a week, for four weeks), immediately after the first dose (166). 
PCr+ ADP +H+ ↔ creatine + ATP 
Discussion and Conclusions ________________________________________________________ 
126 
Moreover, in the same study, the creatine content of heart mitochondria was increased, 
evidencing the loss of mitochondrial membrane permeability (166). 
Besides the ATP depletion observed in MTX48 hearts, plasma lactate levels were 
increased in this group in comparison with MTX22 and control levels (Manuscript III), 
which was accompanied by increases in the cardiac relative mass, suggesting a cardiac 
failure condition. Increased levels of plasma lactate are suggestive of lactic acidosis and 
occurs in response of tissue hypoxia, uncoupling of oxidative phosphorylation, generalized 
cachexia (due to increased anaerobic glycolysis in the skeletal muscle), congestive heart 
failure, and in situations where the hepatic clearance is compromised (which can also be 
the case regarding the hepatic damage described in Manuscript IV) (136,167). However, 
in failing hearts, the heart assumes the fetal pattern, switching the main substrate of 
energetic sources from fatty acids to glycolysis with a reduced oxidative metabolism 
(136,168), thus, more lactate is produced and lower levels of ATP is generated (136). 
The glycolytic pathway and the tricarboxylic acid cycle usually give small 
contributions to the cardiac ATP content, being the major source of ATP the mitochondrial 
oxidative phosphorylation, which is usually enough to support the normal needs of the 
heart, even when the heart’s demand is increased (162). The factors required by the 
mitochondria are usually obtained after β-oxidation of fatty acids in the mitochondria and 
peroxissomes. Thus, when ATP supply and demand are mismatched, it can indicate a 
defect in mitochondrial synthesis of ATP. For instance, in ischemic, hypoxic and 
cardiomyopathic hearts, the cell’s ability to match ATP supply and demand is disrupted 
and the depletion of the cardiac energy pool is accompanied by a dysfunction on 
mitochondrial ATP turnover mechanisms (169). 
IV.6. MTX-induced mitochondrial toxicity 
In general, mitochondria perform central functions in the cardiac cell such as energy 
supply, regulation of reactive species formation, buffer cytosolic calcium, and regulation of 
apoptosis (155). Mitochondria have two membranes: the outer membrane is rich in 
cholesterol and is permeable to ions and solutes up to 14KDa while the inner membrane 
contains membrane proteins that transport selected ions and metabolites across the 
membrane. Additionally, the inner membrane delimits the matrix, where the mitochondrial 
DNA and soluble enzymes such as those from the tricarboxylic acids cycle and β-
oxidation are found (170). The respiratory chain is located in the mitochondrial inner 
membrane and is responsible for ATP production through the oxidation of NADH and 
ubiquinol, which transfer electrons to the oxygen through the respiratory chain complexes. 
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There are five mitochondrial respiratory chain complexes: complex I (NADH:ubiquinone 
reductase), complex II (succinate:ubiquinone reductase), complex III 
(ubiquinol:cytochrome c reductase), complex IV (cytochrome c oxidase), and complex V 
(ATP synthase). Mitochondrial respiration promotes the proton ejection without charge 
compensation. Hence, the electrochemical gradient and free energy provided are enough 
to serve as motive force to the ATP synthesis (96,155). 
Heart muscle is a highly oxidative tissue that produces more than 90% of its energy 
through mitochondrial respiration (136). Mitochondria occupy about 30% of cardiomyocyte 
space, suggesting its relevance for cardiac performance (136,162). Cardiac mitochondria 
have a large number of cristae, which is justified due to the high energetic demand and 
respiratory activity of the cardiac tissue (96). Considering that mitochondrial oxidative 
phosphorylation is the major source of ATP, mitochondrial dysfunction and consequent 
disruption of energy metabolism are associated to rapid depletion of cellular energy 
reserves (169). 
It was already demonstrated that mitochondria is involved in doxorubicin-induced 
cardiomyopathy. After the doxorubicin acceptance of unpaired electrons from complex I of 
the mitochondrial electron transport chain, the resulting reactive species are stabilized by 
superoxide dismutase and by reacting with mitochondrial reducing equivalents such as 
GSH. As a consequence, GSH oxidation leads to the MPT opening and, subsequently, 
mitochondrial swelling, depolarization, loss of calcium regulation, and inhibition of 
mitochondrial bioenergetics (97).  
The H9c2 cells incubation with MTX (100nM and 1µM) caused the late inhibition of 
ATP synthase expression and activity (Manuscript II), suggesting that MTX causes a 
direct inhibition of ATP synthesis. However, decreased levels of ATP were observed 
earlier than ATP synthase expression and activity inhibition (table 4), suggesting that 
other effects besides interference with ATP synthase are involved in intracellular ATP 
depletion. Considering that this cell model privileges the glycolytic pathway, another 
possible target of MTX is enzymes involved in glycolysis. Other possibilities are the lack of 
nucleotides (which was not investigated by us) or increased consumption of ATP by 
diverse biochemical mechanisms. The late (96h) inhibition of ATP synthase and 
expression induced by MTX, to the best of our knowledge, was described for the first time 
by our works. Additionally, in this cell model, the mitochondrial membrane potential was 
hyperpolarized after MTX (100nM and 1µM) incubation at 24, 48, and 96h. At 24h 
incubation with 1µM MTX neither the hyperpolarization of mitochondrial membrane 
potential nor the elevation of calcium intracellular levels were observed. In the other 
experimental conditions tested (48 and 96h), the mitochondrial membrane potential was 
elevated simultaneously with rise of intracellular calcium levels, which may difficult to 
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assert which was the first event. Even so, the mitochondrial membrane potential may be 
elevated as an attempt to provide motive force to restore the energetic homeostasis that is 
altered given the early decreases in the ATP levels. At 96h incubation, the decreases in 
the ATP-synthase content and activity are accompanied by increases in the reactive 
species generation, suggesting a possible connection between events (Manuscript II). The 
chronology of the energetic imbalance observed in the H9c2 studies was summarized in 
the table 4.  
Table 4: Diagram representing the chronogram of energetic/mitochondrial changes 
observed in the H9c2 cells after incubation with MTX. (yes = presence of the effect, n.o = 
not observed [absence of the effect], n.d= not determined). The results were obtained 
after comparison with control cells. 
 
  MTX 100nM MTX 1µM 
  24h 48h 96h 24h 48h 96h 
Decreases in the intracellular ATP levels yes yes yes yes yes yes 
Inhibition of ATP synthase expression n.o n.o yes n.o n.o yes 
Inhibition of ATP synthase activity n.d n.d yes n.d n.d yes 
Hyperpolarization of mitochondrial 
membrane potential yes yes yes n.o yes yes 
Increases in the intracellular calcium 
levels yes yes yes n.o yes yes 
Increases in the reactive species 
generation n.d n.d yes n.d n.d yes 
 
Considering the suggested mitochondrial injury, L-carnitine was used to study the 
possible protection of MTX effects in the H9c2 cell model. First, the transport of fatty acids 
across mitochondrial membrane is only possible when these substrates are attached to 
carnitine (171), allowing their β-oxidation. Furthermore, L-carnitine improves the trans-
esterification/excretion of acyl-CoA esters, the oxidation of α-ketoacids, and the removal 
of toxic acylcarnitine ester from the mitochondria (171,172). However, although L-carnitine 
(1mM) is considered a mitochondrial enhancer, under our experimental conditions it did 
not protect the H9c2 cells from the cytotoxicity induced by MTX incubation (96h), 
evaluated through the MTT reduction test. This lack of protection probably occurs 
because the MTX-induced cytotoxicity has a mitochondrial mechanism other than the 
ones targeted by L-carnitine. In fact, our results suggest that MTX causes important 
energetic crises, directly affecting ATP content and synthesis. Even so, in contrast to our 
data, protective effects of L-carnitine were observed in MTX treated mice: the 
administration of L-carnitine decreased the lethal toxicity of MTX (LD50 MTX 
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alone=15.2mg/kg vs. LD50 MTX+L-carnitine 200mg/kg=21.8mg/kg) (173), which may 
indicate that in vivo, the enhancement of mitochondrial function elicited by L-carnitine may 
favor a better response to MTX. Nonetheless, regarding mice with solid Ehrlich tumor, the 
co-administration of L-carnitine did not present any potentiating effect on the antitumor 
efficacy of MTX considering the tumor growth rate or increased the survival of mice (174). 
In fact, the acetyl ester of carnitine (L-acetyl-carnitine) may impair the antineoplastic 
treatment since the combined therapy of MTX and acetyl-L-carnitine in mice with solid 
Ehrlich tumor showed a higher occurrence of metastases with broad dissemination to the 
kidneys, lung, heart, and mediastinum (175), greatly harming the clinical efficacy of MTX. 
Trying to evaluate MTX-induced mitochondrial toxic effects in vivo, the cumulative 
mitochondrionopathy of MTX was studied using male adult Wistar rats (Manuscript III). 
Early and late toxic effects (two days vs. 28 days after reaching the MTX total cumulative 
dose - MTX22 and MTX48 groups, respectively) were evaluated in order to better 
understand the (mal)adaptive responses involved in MTX-induced cardiotoxicity 
(Manuscript III). The mitochondrial functional and morphological disturbances were 
demonstrated in both treated groups and were more pronounced in the late time point 
(Manuscript III). In the present study, the mitochondrial cristae were well defined and 
swelling was absent, thus, the mitochondrial morphologic changes were restricted to giant 
and collapsed mitochondria (Manuscript III). One hypothesis that could explain this finding 
is the MTX ability to intercalate into the DNA molecule causing single and double breaks 
and inhibiting DNA and RNA synthesis (22), compromising the mitochondrial turnover. 
Other changes in the mitochondria morphology were already reported after MTX 
administration. A chronic administration regimen of MTX (0.2mg/kg, weekly for 12 weeks, 
reaching a total cumulative dose of 2.4mg/kg) in female BALB/c mice caused late cardiac 
mitochondrial degenerative changes, such as mitochondrial swelling, partial clearing of 
the matrix, and the appearance of myelin figures (50). Moreover, comparative studies with 
MTX and doxorubicin demonstrated an increased mitochondrial toxicity potential of MTX 
compared to doxorubicin (102). 
In our in vivo study, in both treated groups (MTX22 and MTX48) increased activity of 
the mitochondrial complex IV was observed. In the activity of complex V dissimilar results 
were shown in different groups: MTX22 had increased levels while in MTX48 the activity 
of complex V decreased (Manuscript III). The increases in the activity of the complex IV 
and V in MTX22 may result from an adaptation of mitochondria to provide more efficiently 
ATP in response to MTX toxic effects. Conversely, in the MTX22 group, no significant 
difference in the ATP cardiac content compared to control rats was observed, showing 
that, at this time point, the increased activity of the complexes appears to be sufficient to 
maintain ATP overall levels, although other mechanisms should not be neglected. 
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However, the increase in complex IV activity was not enough to support the ATP demand 
when accompanied by decreased mitochondrial complex V activity, as observed in the 
MTX48 group, as levels of cardiac ATP significantly decrease. A reduction in the electron 
transfer activity of state III and a concomitant uncoupling of oxidative phosphorylation 
were already observed in cardiac mitochondria isolated from MTX treated female rats 
(1mg/kg, twice a week, for four weeks reaching a cumulative dose of 8mg/kg) (166). 
Furthermore, cardiac mitochondria showed a reduction in the electron transfer and the 
respiratory chain activity, uncoupling of oxidative phosphorylation with consequent 
relevant drop in the Na+/K+ ATPase activity (166). It is also important to refer that besides 
the association of the ATP decreased levels and an inhibited ATP synthesis suggested by 
the late decreases in the activity of ATP synthase complex presented here, changes in the 
ATP levels in the failing myocardium can also be related to the loss of total tissue purines 
(165), which were not evaluated in our studies. 
In contrast to the mitochondrial effects demonstrated in vivo, the incubation of MTX 
(10nM, 100nM, and 1µM) with cardiac mitochondria isolated from untreated rats did not 
cause any change in the mitochondrial functionality evaluated by the distribution of TPP+ 
assay. In contrast, mitochondria isolated from two animals from the MTX48 group 
presented an increased lag phase, demonstrating a difficulty to repolarize and sustain the 
mitochondrial potential, which is consistent with an inhibition of ATP synthesis. As already 
referred, MTX metabolism exerts a pivotal role to the MTX-induced toxicity. Thus, one 
possibility is that the direct toxic effect mediated by MTX in vitro may be residual and 
insufficient to elicit significant alterations in this model without being biotransformed. 
Hence, differences in the metabolism rate might be behind the intersubject variability 
observed in the clinical evaluations of the treated animals presented in the present work 
(discussed further) and in the human MTX therapy. 
IV.7. Types of cardiomyopathies 
Diseases of the myocardium usually produce abnormalities in cardiac wall thickness 
and chamber size, and mechanical and/or electrical dysfunction, which are associated 
with significant morbidity and mortality (176). Cardiomyopathies are classified in three 
forms: restrictive, hypertrophic, and dilated (176,177) that will be described in the following 
paragraphs. 
The restrictive cardiomyopathy is the less frequent and it is a disorder characterized 
by an impaired ventricular filling during diastole due to a less compliant ventricle without 
changes in the systolic function of the left ventricle (176).  
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The cardiac hypertrophy is classified in concentric hypertrophy or eccentric 
hypertrophy (162,177). In concentric hypertrophy, new contractile protein units are 
disposed in parallel resulting in cardiomyocyte enlargement, while in eccentric 
hypertrophy the assembly of new contractile protein units occurs in series, producing 
increases in the length of cardiomyocytes (162). Essentially, in affected individuals, a 
disproportionate thickening of the interventricular septum when compared with the free 
wall of the left ventricle occurs (176). Additionally, hypercontractile systolic function 
resulting in exaggerated pump function is accompanied by a poor relaxation of the heart 
resulting in diastolic dysfunction (177). The hypertrophy involves alteration of components 
of sarcomere and, histologically, a massive hypertrophy of the muscle fibers, mainly in the 
interventricular septum, acute interstitial fibrosis, and loss of muscle fiber organization are 
observed (176). Both hypertrophy and restrictive cardiomyopathies can cause heart failure 
due to the diastolic impairment while the mechanism involved in the heart failure related to 
dilated cardiomyopathy is mainly systolic dysfunction (176). 
Dilated cardiomyopathy is the most prevalent cardiomyopathy and it is characterized 
by increased volume of cardiac chambers (176,177). Histologically, some hypertrophy can 
be seen, although, it is not as pronounced as in the hypertrophic cardiomyopathy. The 
most abundant microscopic feature of dilated cardiomyopathy is the abundant interstitial 
fibrosis without loss of organization in the muscle fibers (176). Moreover, it involves 
alterations in a wide variety of proteins, predominantly of the cytoskeleton, but also 
affecting the sarcomere, mitochondria, and nuclear envelope (176,177). Although 
hypertrophic and dilated cardiomyopathies have different morphologies and subcellular 
phenotypes, they share the same clinical complications, such as shortness of breath, easy 
fatigability, inability to tolerate physical exercise, fainting, light headedness, sweating at 
rest and in some cases, increased heart rate, enlargement of the liver, and sudden death 
(177).  
Dilated cardiomyopathy is most commonly associated to anthracycline treatment, as 
evidenced by hystopathomorphological data (97), but sometimes children receiving drugs 
from this therapeutic class can develop restrictive cardiomyopathy (3,176). The cardiac 
damage shown in the histology performed in the present study was observed in both 
ventricular sides without differences, suggesting that both sides were equally affected. 
Considering cardiac abnormalities induced by MTX, in our studies, light microscopy of 
right and left cardiac ventricles from rats subjected to MTX treatment (MTX22 group) 
revealed dispersed cellular and interstitial edema, diffusion of inflammatory cells, and 
proliferation of connective tissue (Manuscript III). In the MTX48 group, dispersed areas of 
an intense proliferation of the connective tissue with abundant cellular infiltration, probably 
by fibroblasts, was observed. The sub-endocardial region was considered more affected 
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compared to the sub-pericardial since the cellular edema and fibrosis were more 
pronounced in this region. The transmission electron microscopy of MTX22 and MTX48 
hearts revealed edema of cardiomyocytes, lysossomal activation in the cardiomyocytes, 
and proliferation of connective tissue and fibroblasts, suggesting a chronic inflammatory 
process probably because of an adaptation/repairing process due to continuous cell 
death. Conversely, abundant collagen deposition in the interstitial space was observed in 
MTX48 group and the heart from these animals presented significant increase in heart 
relative mass. Interstitial reparative fibrosis typically occurs as a response to the loss of 
myocytes due to myocardial ischemia or senescence (178).  
The increase in the cardiac relative mass was not accompanied by differences in the 
total cardiac protein levels. Thus, our results suggest that the increase of cardiac relative 
mass was related to water retaining instead of hypertrophy. Cellular edema was observed 
as an increase of the cellular perimeter. It can be distinguished from cardiac hypertrophy 
since hypertrophic cardiomyocytes present homogenous eosinophilic cytoplasm because 
of the close contact of myofibrils. In the cellular edema, however, it is observed the 
separation of myofibrils and increased amount of water within the cell. Thus, in this 
condition, the eosinophilic coloration of cytoplasm remains irregular (white areas and 
vacuoles between the myofibrils) (Figure 2, manuscript III). The accumulation of 
connective tissue in response to continuous cardiomyocyte death may also contribute to 
the increased cardiac relative mass, however, the method used to quantify protein does 
not detect collagen. These changes in the cardiac collagen network are seen in response 
of pressure/volume overload, after myocardial infarction (178), and, as already mentioned, 
in dilated cardiomyopathy (176). 
Microscopic data from heart of MTX-treated rats evidenced the presence of digiform 
endothelial projections suggesting endothelial degeneration (Manuscript III). This finding 
was consistent in all MTX treated rats, in both right and left ventricles, and it was also 
seen in our previous pilot studies with higher doses (three cycles of 5 and 10mg/kg) in a 
dose-dependent manner (data not shown). Similar endothelial alterations were reported in 
intestinal epithelium and in human skeletal muscle capillaries after prolonged ischemia 
(179,180). Thus, it is possible that this microscopic observation may be related to cardiac 
hypoxia, which is in accordance with the signs of small caliber arteries obstruction seen in 
the histology (Manuscript III). 
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IV.8. Intersubject variability in the in vivo study 
During the in vivo MTX treatment (Manuscripts III and IV), rats received three cycles 
of 2.5mg/kg MTX at days 0, 10, and 20, reaching the cumulative dose of 7.5mg/kg or 
48mg/m2 at the end of the third cycle. Clinical evaluations of rats showed great variability, 
especially in the MTX48 group after the third cycle of treatment. Also the clinical 
responses during the experiment were already heterogenous: on the day 22, two rats from 
the MTX22 group presented moderate piloerection. On the day 25, three animals from the 
group MTX48 showed intense signals of toxicity, namely slight dehydratation, cyanosis, 
and slight bleeding. The cyanosis seems to be a common observation related to MTX 
treatment considering that female rats previously treated with MTX (1mg/kg, twice a week, 
for four weeks) presented a blue coloration of the skin and tissues, color that was also 
observed in isolated mitochondria from the heart of these rats (166). In humans, 
discoloration of the nails was already associated to MTX therapy and it was related to 
early anemia (181). One of those clinically debilitated animals presented clinical recover, 
but the other two died on day 35, 15 days after the end of treatment. The death 
circumstances of those animals were not elucidated, but we speculate that it might be 
related with the cardiac ATP depletion or with a non-reverted myelossupression. 
Paradoxically, the two animals that complete the MTX48 group did not present any 
significant clinical observed change during all the experiment. Variations in the clinical 
responses were already associated to MTX treatment in humans, and it highlights that 
intersubject variation is crucial in the MTX toxic effects (26). 
The variability of MTX effects was also suggested by the increases in the standard 
deviations in the % of relative body weight gain after the third cycle until the day 30 
(Manuscript III). Animals treated with MTX showed a tendency to decrease the relative 
body weight gain compared to control group after the second cycle. These decreases 
were more evident and statistically significant after the third cycle until day 30 and were 
not accompanied by changes in food and water consumptions. This change is indicative 
of toxicity. MTX (6, 9, and 12mg/kg) treatment was already associated with a lower body 
mass gain in mice with Ehrlich tumor (175). Transient changes in the food and water 
consumption were individually observed in the animals that presented clinical toxic 
manifestations, namely decreases in the water consumption in rats presenting 
dehydration and fluctuations on food consumption in those animals presenting bleeding 
(data not shown). 
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IV.9. MTX-induced hepatotoxicity  
The MTX sub-chronic treatment of rats induced an important hepatotoxicity. Firstly, 
the MTX-induced hepatic damage was clearly evidenced at necropsy by the macroscopic 
changes observed in the MTX treated livers (Manuscript IV). Excised livers presented mild 
edema (characterized by the beaded edge and brilliant aspect) and rigid consistency, 
being more severe in the MTX48 group than in the MTX22 group. Signals of the 
cumulative hepatic injury were also observed in both treated groups and were 
characterized by macro- and microscopic changes in the hepatic architecture, biochemical 
alterations, and decreases in the hepatic protein levels in the MTX22 group, late 
decreases in the hepatic ATP content and by the increases in the GSHt, GSH, and GSSG 
hepatic levels in MTX48 group. 
Signals of the cumulative hepatic injury are observed in the earlier time point 
(MTX22 group), namely by changes in plasma parameters (decreases in the total plasma 
protein, ALT, alkaline phosphatase, triglycerides, and transferrin and increases in C4 
complement, cholesterol, and iron levels) and decreases in the hepatic total protein levels. 
These data suggest a hepatic dysfunction, seen in lower plasma hepatic enzyme levels 
but higher free cholesterol as seen in other reports (182,183). This increase in the plasma 
cholesterol levels in the MTX22 group is consistent with the mild steatosis observed in the 
respective histology, which can be related to the decreased hepatic synthesis of 
lipoproteins (60). The impairment of hepatic functionality is also evidenced by early 
increases in the iron levels and decreases in plasma triglycerides in both treated groups, 
being the last molecules mainly synthesized by the hepatocytes. 
The hepatic protein synthesis seems to be impaired in both treated groups as 
evidenced by the low levels of plasma biochemical parameters such as ALT, alkaline 
phosphatase, and transferrin (Manuscript IV). AST activity remained unchanged in both 
treated groups when compared to control levels. The lack of changes in AST activity might 
be related to its slower released pattern in comparison to ALT (175). For this reason and 
considering that ALT is primarily found in the liver, while AST is also distributed among 
other tissues such as heart, kidney, brain, and muscle, ALT is the standard biomarker of 
hepatotoxicity (184). In fact, as already mentioned, in humans, acute hepatotoxicity of 
MTX manifests as transient increases in the activity of both liver enzymes (9). In mice with 
Ehrlich tumor treated with MTX single dose (9 and 12mg/kg), AST activity increased when 
compared to control and ALT activity increased only with the higher dose of MTX after 14 
days of MTX-treatment (175). Given the AST broad distribution, rises in its activity in the 
absence of concomitant ALT increases are frequently interpreted as indicative of 
abnormalities in tissues such as the heart (184). Thus, it is possible that the changes in 
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the liver aminotransferases after MTX single doses observed in the study performed by 
Niang and co-workers are related to the classic MTX-cardiotoxicity. In that administration 
regimen, only the higher MTX dose might have elicited hepatotoxicity, considering the 
rises in ALT activity observed with this dose (175). 
The lower plasma enzyme levels observed in Manuscript IV suggest that protein 
turnover is decreased. Moreover, decreases in the hepatic synthesis of these enzymes 
were considered an outcome to the (sub)chronic hepatotoxicity induced by others 
xenobiotics (60,183,185,186). Increases in the unconjugated bilirubin (observed indirectly, 
since it was shown by decreases in conjugated bilirubin and no significant changes in total 
bilirubin) in both treated groups are suggestive of impaired conjugation with glucuronides. 
Sub-clinical unconjugated hyperbilirubinemia is related to antituberculosis therapy, and it 
is attributed to the inhibition of the bile salt exporter pumps (187). 
The apparent recovery of the hepatic total protein levels on MTX48 compared to 
MTX22 does not mean functionality gain, considering the alterations in MTX48 hepatic 
ATP and plasma protein levels. Indeed, instead of recovery, the hepatic lesion was more 
pronounced in the later time point (MTX48 group) as seen by liver histology. In rats, the 
liver is able to repair from hepatic injury in five to seven days (188). Even so, despite the 
adaptive/repair ability of the liver to react to a hepatic injury, this organ seems to be 
vulnerable to MTX toxic effects since that mice treated with MTX (15mg/kg) presented 
significant changes in the liver microscopic architecture that were not reverted until five 
days after the MTX-administration (49). In our study, histologic data did not revealed 
signals of a hepatic damage secondary to heart failure. As already stated, MTX and its 
toxic metabolite are retained in the hepatic tissue (Manuscript I) and the continued hepatic 
exposure might lead to prolonged hepatic injury. Furthermore, in the later time point, the 
classic late cardiotoxicity of MTX (which was described in the Manuscript III) may 
contribute to promote a secondary hepatic lesion (189).  
Microscopic evaluations of liver showed a huge proliferation in the Kupffer cells, 
hepatic edema, and collagen proliferation, which are indicative of an inflammatory 
process. Indeed, that was corroborated by the significant increases in the plasma C4 
complement levels since this component is synthesized by Kupffer cells (190). Previously, 
a single dose administration of MTX (15mg/kg) was enough to cause an intense hydropic 
vacuolization of the cytoplasm, necrosis areas, picnosis, and nuclear lysis in the hepatic 
tissue, observed five days after treatment (49). 
As already discussed, the cumulative late MTX-induced hepatotoxicity was 
associated with oxidative stress as seen by significant increases in the hepatic levels of 
GSHt, GSH, and GSSG observed in the MTX48 group. Moreover, to the best of our 
knowledge, it was the first time that hepatic late energetic imbalance was associated to 
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MTX-induced hepatotoxicity. In the present study, the inhibition of the hepatic protein 
synthesis occurred prior to the decreases in the ATP content in the liver. This early effect 
might be related to the MTX ability to inhibit protein synthesis (2). The late decrease in the 
hepatic ATP levels was observed even 28 days after the last MTX administration. 
Decreases in the ATP hepatic levels are observed in the human nonalcoholic 
steatohepatitis (191) and are associated to covalent binding of drugs to intracellular 
proteins (192). Thus, once again these effects can be attributed to the ability of MTX and 
naphtoquinoxaline metabolite to accumulate in the liver (26). MTX persistence in the cells 
is related to its strong affinity for cellular macromolecules and membranes (35,44).  
IV.10. MTX-induced hematotoxicity 
In our in vivo study, the MTX-induced hematological toxic effects were evidenced by 
a notorious early bone marrow depression on MTX22 group, characterized by the 
significant decreases in red blood cell (RBC) count, HCT, and reticulocytes, as well as in 
WBC count, as compared to control. Additionally, an anemic condition was observed 
since Hb levels were significantly decreased. Besides being a signal of hepatic lesion, the 
increase in the plasma iron might be related to an increase in iron absorption to overcome 
the reduction in RBC. Increased of MPV and a marked bone marrow suppression were 
observed in the MTX22 group, as shown by the absence of circulating reticulocytes. 
Recovery signals of the hematopoiesis were observed in the MTX48 group, namely by 
increases in reticulocytes when compared to control. Additionally, increase of MCH and 
MCV levels were observed when compared with the control. The observed macrocytosis 
and anisocytosis are associated with increases in the reticulocytes count (Manuscript IV). 
The reduction in blood cells is probably mainly due to marrow suppression. Caution is 
needed in the interpretation of the cause of the anemia since disturbances in the iron 
metabolism (increases in the iron plasma levels and decreases in the transferrin levels) 
and increases in the non-conjugated bilirubin levels can represent confounding factors. It 
is important to take into account that, simultaneously to a hematologic disturbance, an 
impaired hepatic function has been established in our model. Despite of hemorrhagic 
clinical signals seen in some MTX-treated rats, no increase in the LDH plasma levels was 
observed. 
As already mentioned, MTX is an immunosuppressive agent that acts by promoting 
apoptosis in antigen-presenting cells and reducing levels of all types of immune cells 
(15,24). Accordingly, the MTX administration caused transient decreases in plasma IgG 
levels in MTX22 rats. In another study that assessed the human safety of MTX, rituximab, 
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ifosfamide, and etoposide combined therapy a significant decrease in the IgG levels in 
treated patients with non-Hodgkin’s lymphoma was demonstrated (193). The IgG is 
synthesized by blood cells and corresponds to about 80% of total immunoglobulin (194). 
Thus, the huge decreases in IgG levels observed in the MTX22 group might be the cause 
of the decreases observed in the total plasma protein levels in this group since albumin 
levels are similar to control levels (data not shown). Additionally, the absence of significant 
differences in the plasma albumin levels might be related to its long turnover (195). 
Conversely, decreases in serum total protein levels without changes in the serum albumin 
levels were already described in MTX single dose (6, 9, or 12mg/kg) treatment in mice 
with Ehrlich tumor (175). 
The presence of micronucleus in MTX22 blood smears was constant in all animals 
from this group, suggesting the genotoxicity capacity of MTX. This genotoxicity could 
underlie an ineffective hematopoiesis, supporting our hematologic data at MTX22 (bone 
marrow suppression). Accordingly, it is well known that MTX causes single and double 
breaks in the DNA (1,2) and also affects the cell cycle at various stages (1,22), with 
known mutagenicity ability.  
The pancytopenia was not proven only because the PLT lineage is not depleted. 
The circulation time of PLT in healthy conditions is about seven to ten days (196). Thus, it 
is possible that, at the time points evaluated, the PLT count was already normalized in 
opposition to other lineages. Moreover, it is in accordance with the reports describing that 
thrombocytopenia is a mild, less common event in the MTX treatment (2). The MPV is 
increased in the MTX22 group and it no changes in the PDW were seen, demonstrating 
that the PLT population is homogeneously macrocytic. Despite the clinical use of this 
parameter is not yet well validated, studies demonstrate an association between enlarged 
MPV and cardiovascular risk because larger PLTs are hemostatically more active, leading 
to higher risk of myocardial infarction (196–198). Pro-inflammatory states frequently 
present PLT with higher volume because cytokines such as interleukines 3 and 6 can 
mediate the production of PLT with higher MPV and metabolic/enzymatically more actives 
(196). 
The myelossupression observed in our work is in accordance to what is observed in 
humans and justifies the importance of monitoring hematological parameters during MTX 
chemotherapy (2). The MTX-induced myelosuppression manifests mostly as leukopenia, 
thus being its main dose-limiting effect (61). In humans, after the administration of high 
dose MTX (38mg/m2, i.p.), the WBC counting returned to normal values within seven days 
(61). However, it is known that patients treated with higher dose regimens tend to present 
a faster blood count recovery (2). Additionally, blood cell counts should be continued after 
MTX-therapy cessation due to the risk of MTX-associated secondary acute leukemia (15). 
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In the present study using clinically relevant doses, RBC and WBC counts, which were 
depressed in the early time point, returned to normal values in the MTX48 (28 days after 
the MTX last cycle) (Manuscript IV).  
IV.11. Conclusions and future perspectives 
 
Four hallmarks are defined as contributing to the pathology of cardiac disease: a 
critical energy loss; a critical accumulation of cellular calcium; effects of reactive species 
formation; and injurious effects of the accumulation of long-chain acyl compounds (169). 
From these, we demonstrated the occurrence of marked energy depletion in vitro and in 
vivo, increased levels of intracellular calcium after MTX incubation in the H9c2 cells, 
increased generation of reactive species only at the longer incubation period of 96h with 
concomitant mitochondrial disturbance. The acyl compounds accumulation was not 
evaluated but the negative results in the protective studies with L-carnitine suggested that 
it did not exert a leading role in the MTX-mediated cytotoxicity. 
MTX induces a relevant cumulative mitochondrionopathy characterized by the 
aberrant mitochondria found in the cardiac tissue after in vivo MTX treatment, the 
disturbances in the mitochondrial complexes and ATP synthesis, and perturbations in the 
mitochondrial membrane potential. MTX interference with the mitochondrial functionality 
and consequent energetic imbalance result in a dysfunctional heart since depleted of its 
energetic content, the cardiac performance is impaired. Hence, this thesis highlights the 
relevance of the MTX-induced mitochondrial toxicity to the cardiomyopathy related to the 
MTX therapy. 
In the opposite of what is observed in the doxorubicin cardiomyopathy, the oxidative 
stress does not seem to occupy a central role in the MTX-mediated cardiac disease. The 
eventual MTX-related oxidative stress does not seem to be related to quinone activation, 
but secondary to energetic loss. Thus, the contribution of the metabolism to the 
cardiotoxicity seems to be more related to the reaction products (for an example, the 
naphtoquinoxaline metabolite, which was demonstrated to accumulates in liver and heart) 
than the sub-products (reactive species generation associated to quinone activation). 
Increased levels of reactive species formation were only observed in a late time point, 
secondary to another significant changes such as energetic depletion, intracellular 
calcium overload, and mitochondrial disturbances. Even so, studies demonstrating the 
inhibition of lipid peroxidation after MTX incubation (29) suggest that MTX may alter the 
antioxidant defenses in some extent and it is worth to be highlighted.  
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It was also demonstrated a relevant hepatotoxicity associated to MTX therapy in 
rats. After 28 days of the last MTX administration, the liver regeneration was limited and 
the hepatic tissue remained with altered levels of glutathione and ATP, which are 
essential for the hepatic function, namely protein synthesis and detoxifying process. 
Despite the direct hepatotoxic potential, cardiotoxic drugs such as MTX, can cause acute 
liver failure as a result of a primary congestive heart failure (189). In the case of 
congestive heart failure, the low cardiac output results in a reduced hepatic blood flow 
(189). However, in the histology of MTX-damaged livers, no signals suggestive of 
congestive heart failure-mediated hepatic lesion were observed. Thus, it is possible that 
MTX exerts a significant direct hepatotoxicity. 
Considering MTX cardiomyopathy, our results demonstrate an abundant interstitial 
fibrosis without loss of organization in the muscle fibers and mitochondrial disorganization, 
suggestive of dilated cardiomyopathy. However, conclusive studies regarding the protein 
alterations after MTX therapy are required to confirm the cardiomyopathy type related to 
MTX treatment. The only protective agents that partially counteracted the cellular lesion 
caused by MTX incubation were metabolism inhibitors. However, despite the evidenced 
metabolic relevance to MTX-cardiomyopathy, bioactivation is also required for the MTX 
pharmacological effects. Hence, blocking MTX systemic metabolism is not a viable 
alternative since it would compromise the antineoplastic treatment. Even so, the studies 
presented within this thesis may open up ways to enhance MTX therapy. 
Regarding future perspectives, the relation between MTX treatment and long-term 
hematotoxicity, which can result in the serious late secondary leukemia, needs to be 
better highlighted. Furthermore, understanding the MTX toxic effects among 
hematopoiesis are the first step to circumvent them and to increase the MTX tolerance 
and safety. Moreover, the intrinsic hepatotoxic potential of chemotherapy is of great 
concern because an altered hepatic function might compromise the therapy and/or 
increase toxic adverse effects (60). Given that relevance, more studies highlighting the 
mechanisms involved in the MTX-induced hepatotoxic potential are needed in order to 
improve therapy. Furthermore, the pharmacological and toxicological potential of the 
metabolites presented in the Manuscript I need to be highlighted. If they have a good 
pharmacological potential and a negligible toxicity, one possibility is to isolate, purify, and 
to explore these promising compounds in preclinical studies. However, it is important to 
point that, in the case of MTX derivatives, long term protocols to assess the toxicity are 
needed. Other future directions aim to define if the MTX pharmacological action is also 
dependent of MTX mitochondrial effects and to explore mitochondrial protective agents to 
counteract the MTX-induced mitochondrionopathy, minimizing cardiac side effects without 
affecting the MTX-pharmacological effectiveness. 
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